Conditions: Healthy Participants
Keywords: etrasimod adults
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 8
Healthy volunteers: yes

Brief summary:
The purpose of this study is to look at how healthy adults process Etrasimod when assessed by wearable sensors. Etrasimod is taken without food and assessments taken by site staff and then by participants after training.

The study is seeking participants who are:

* Aged 18 or older
* Male or female who are healthy as determined by medical assessment
* Body-mass index (BMI) of 16 to 32, and a total body weight \> 50kg.

The study will take up to 9 weeks, including the screening period. Participants will have to stay at the study clinic for at least 2 nights, in each of 2 study periods.

Participants will take Etrasimod as a tablet by mouth without food. Blood samples will be taken both before and after participants take Etrasimod. Participants will also use wearable devices to assess blood pressure, heart rate and take further blood samples. A follow-up phone call will be made 20 to 27 days after the last study period.

Detailed description:

Arms:
arm 1: Single oral dose of etrasimod 2mg tablet under fasted conditions with site staff led assessments and training on how to use wearable sensors followed by single oral dose 2mg tablet under fasted conditions with participant led assessments with wearable sensors.

Interventions: intervention 1: Etrasimod Immediate Release (IR)
Intervention descriptions: intervention 1: An immediate release tablet

Protocol document:
Prot_000.pdf: 
Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 1
Title Page
SUB STUDY
A PHASE 1, OPEN-LABEL, SINGLE DOSE, FIXED-SEQUENCE CROSSOVER SUB 
STUDY TO DETERMINE THE PHARMACOKINETICS USING TASSO DEVICE 
AND SAFETY AND TOLERABILITY USING WEARABLE MONITORING 
DEVICES FOLLOWING SINGLE ORAL DOSES OF ETRASIMOD 2 MG IR 
TABLETS IN HEALTHY ADULT PARTICIPANTS IN A HYBRID 
DECENTRALIZED CLINICAL TRIAL DESIGN
Study Intervention Number:
PF-07915503
Study Intervention Name:
Etrasimod
US IND Number:
125154
EudraCT/EU CT Number:
2023-508119-22-00
ClinicalTrials.gov ID:  
Not applicable
Pediatric Investigational Plan Number:
Not applicable
Protocol Number:
C5041050
Phase:
1
Sponsor Legal Address:
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001
Brief Title: A Sub Study to Learn About the Study Medication Called Etrasimod 
Tablets in a Hybrid Decentralized Clinical Trial Setting
This document and accompanying materials contain confidential information belonging to Pfizer. Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by applicable law) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer 
must be promptly notified.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 2
Document History
Document
Version Date
Sub Study Protocol Amendment 2 (C5041050)
06 Nov 2023
Sub Study Protocol Amendment 1
12 Oct 2023
Sub Study Protocol
11 Sep 2023
Amendment 1 (C5041034)
02 Jun 2023
Original Protocol (C5041034)
03 Apr 2023
This amendment incorporates all revisions to date, including amendments made at the 
request of country health authorities and IRBs/ECs and any global protocol administrative 
change letter(s). 
Protocol Amendment Summary of Changes Table
Sub Study Protocol Amendment 2 (06 Nov 2023)
Overall Rationale for the Amendment: The Sub Study Protocol was amended to change 
the protocol number as summarized below:
Description of 
Change
Brief Rationale
Section # and 
Name
Non-substantial Modification(s)
Change of protocol 
number for the 
DCT Sub Study 
from C5041034 to 
C5041050.
Since the initial approval, the DCT Sub Study 
protocol (including Amendment 1) is set up as
a stand-alone document. The Sub Study 
protocol (EudraCT/EU CT No. 2023-508119-
22-00) was approved with the same protocol 
number C5041034 as the main study protocol 
(EudraCT/EU CT No. 2023-504411-32-00).
However, to align with the requirements of 
Pfizer SOPs and data management systems, a 
separate unique protocol number was required 
for the Sub Study. This Amendment 2,
reflecting the new protocol number, is 
planned to be implemented in advance of the
first participant first visit (FPFV) milestone 
for the Sub Study.
These changes do not affect the main study 
C5041034 protocol.
Title Page, Header,
Section 1.1 
Regulatory Agency 
Identification 
Number(s)


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 3
Description of 
Change
Brief Rationale
Section # and 
Name
Protocol number 
added to Document 
History Table
For clarification and tracking.
Document History 
Table
Sub Study Protocol Amendment 1 (12 Oct 2023)
Overall Rationale for the Amendment: The Sub Study Protocol was amended to address 
queries from EU regulators following submission of an initial clinical trial application; the 
changes are summarized below:
Description of 
Change
Brief Rationale
Section # and Name
Non-substantial Modification(s)
Exclusion Criterion #1, 
changed the time frame 
prior to study 
intervention from ≤8 
weeks to ≤6 months.
According to the IB, etrasimod is 
contraindicated in patients who in the 
last 6 months have experienced a 
myocardial infarction, unstable angina 
pectoris, stroke, transient ischemic 
attack, decompensated heart failure 
requiring hospitalization, or New York 
Heart Association Class III/IV heart 
failure.
Section 5.2. 
Exclusion Criteria
and Section 2.3.1. 
Risk Assessment
Specify 
ophthalmologic 
examination by 
ophthalmologist as part 
of physical 
examination 
According to the IB, macular edema is 
an important identified risk which 
requires specific ophthalmologic 
monitoring. Therefore, an 
ophthalmologic examination by an 
ophthalmologist is included at baseline 
(Screening) and for clinical monitoring 
of any signs or symptoms throughout the 
trial, as needed.
Section 1.3. Schedule 
of Activities, Section 
2.3.1. Risk 
Assessment, and 
Section 8.3.1. 
Physical 
Examinations


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 4
TABLE OF CONTENTS
LIST OF TABLES.....................................................................................................................9
1. PROTOCOL SUMMARY...................................................................................................10
1.1. Synopsis ..................................................................................................................10
1.2. Schema ....................................................................................................................17
1.3. Schedule of Activities .............................................................................................18
2. INTRODUCTION ...............................................................................................................24
2.1. Study Rationale .......................................................................................................24
2.2. Background .............................................................................................................24
2.2.1. Nonclinical Pharmacology..........................................................................25
2.2.2. Nonclinical Pharmacokinetics and Metabolism .........................................25
2.2.3. Nonclinical Safety ......................................................................................25
2.2.4. Clinical Overview.......................................................................................26
2.2.4.1. Pharmacokinetic Overview of Etrasimod .................................26
2.2.4.2. Safety Overview of Etrasimod ..................................................27
2.3. Benefit/Risk Assessment.........................................................................................27
2.3.1. Risk Assessment.........................................................................................28
2.3.2. Benefit Assessment.....................................................................................31
2.3.3. Overall Benefit/Risk Conclusion................................................................31
3. OBJECTIVES AND ENDPOINTS.....................................................................................31
4. STUDY DESIGN.................................................................................................................31
4.1. Overall Design.........................................................................................................31
4.2. Scientific Rationale for Study Design.....................................................................33
4.2.1. Rationale for ECG Measurements..............................................................33
4.2.2. Rationale for PR and BP Monitoring..........................................................33
4.2.3. Choice of Contraception/Barrier Requirements .........................................33
4.3. Justification for Dose ..............................................................................................34
4.4. End of Study Definition ..........................................................................................34
5. STUDY POPULATION......................................................................................................34
5.1. Inclusion Criteria.....................................................................................................34
5.2. Exclusion Criteria....................................................................................................35
5.3. Lifestyle Considerations..........................................................................................39


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 5
5.3.1. Contraception..............................................................................................39
5.3.2. Meals and Dietary Restrictions...................................................................39
5.3.3. Caffeine, Alcohol, and Tobacco .................................................................40
5.3.4. Activity .......................................................................................................40
5.3.5. Vaccination(s).............................................................................................40
5.4. Screen Failures ........................................................................................................41
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY.................................41
6.1. Study Intervention(s) Administered........................................................................41
6.1.1. Administration............................................................................................42
6.1.2. Medical Devices .........................................................................................43
6.2. Preparation, Handling, Storage, and Accountability...............................................43
6.2.1. Preparation and Dispensing........................................................................44
6.3. Assignment to Study Intervention...........................................................................45
6.4. Blinding...................................................................................................................45
6.5. Study Intervention Compliance...............................................................................45
6.6. Dose Modification...................................................................................................45
6.7. Continued Access to Study Intervention After the End of the Study......................45
6.8. Treatment of Overdose............................................................................................45
6.9. Prior and Concomitant Therapy..............................................................................46
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL...........................................................................46
7.1. Discontinuation of Study Intervention ....................................................................46
7.1.1. Liver Injury.................................................................................................47
7.1.2. ECG Changes..............................................................................................47
7.1.3. Pregnancy ...................................................................................................48
7.1.4. COVID-19 ..................................................................................................48
7.2. Participant Discontinuation/Withdrawal From the Study.......................................48
7.2.1. Withdrawal of Consent...............................................................................49
7.3. Lost to Follow-Up ...................................................................................................49
8. STUDY ASSESSMENTS AND PROCEDURES...............................................................49
8.1. Administrative and Baseline Procedures.................................................................49
8.1.1. Baseline Procedures....................................................................................51


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 6
8.2. Efficacy Assessments..............................................................................................51
8.3. Safety Assessments .................................................................................................51
8.3.1. Physical Examinations................................................................................51
8.3.2. Vital Signs ..................................................................................................52
8.3.2.1. Blood Pressure and Pulse Rate..................................................52
8.3.2.2. Temperature ..............................................................................52
8.3.3. Electrocardiograms.....................................................................................52
8.3.4. Clinical Safety Laboratory Assessments ....................................................53
8.3.5. COVID-19 Specific Assessments...............................................................54
8.3.6. Pregnancy Testing ......................................................................................54
8.4. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................54
8.4.1. Time Period and Frequency for Collecting AE and SAE Information.......55
8.4.1.1. Reporting SAEs to Pfizer Safety...............................................55
8.4.1.2. Recording Nonserious AEs and SAEs on the CRF...................55
8.4.2. Method of Detecting AEs and SAEs ..........................................................56
8.4.3. Follow-Up of AEs and SAEs......................................................................56
8.4.4. Regulatory Reporting Requirements for SAEs...........................................56
8.4.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure.....................................................57
8.4.5.1. Exposure During Pregnancy......................................................57
8.4.5.2. Exposure During Breastfeeding ................................................58
8.4.5.3. Occupational Exposure .............................................................59
8.4.6. Cardiovascular and Death Events...............................................................59
8.4.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................59
8.4.8. Adverse Events of Special Interest.............................................................59
8.4.8.1. Lack of Efficacy........................................................................59
8.4.9. Medical Device Deficiencies......................................................................59
8.4.9.1. Time Period for Detecting Medical Device Deficiencies .........60
8.4.9.2. Regulatory Reporting Requirements for Device 
Deficiencies .......................................................................................60
8.4.10. Medication Errors.....................................................................................60
8.5. Pharmacokinetics ....................................................................................................61


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 7
8.6. Genetics...................................................................................................................63
8.6.1. Specified Genetics ......................................................................................63
8.6.2. Retained Research Samples for Genetics ...................................................63
8.7. Biomarkers ..............................................................................................................63
8.8. Immunogenicity Assessments.................................................................................63
8.9. Health Economics ...................................................................................................63
9. STATISTICAL CONSIDERATIONS ................................................................................63
9.1. Statistical Hypotheses .............................................................................................63
9.2. Analysis Sets ...........................................................................................................63
9.3. Statistical Analyses .................................................................................................64
9.3.1. Efficacy Analyses .......................................................................................64
9.3.2. Safety Analyses ..........................................................................................64
9.3.3. Pharmacokinetic Analyses..........................................................................64
9.3.4. Micro Sampling and Venous Sampling......................................................65
9.4. Interim Analyses .....................................................................................................65
9.5. Sample Size Determination.....................................................................................66
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS..........................................................................................................67
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations...............67
10.1.1. Regulatory and Ethical Considerations ....................................................67
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................67
10.1.2. Financial Disclosure .................................................................................68
10.1.3. Informed Consent Process ........................................................................68
10.1.3.1. Electronic Consent ..................................................................69
10.1.4. Data Protection .........................................................................................69
10.1.5. Committees Structure ...............................................................................69
10.1.5.1. Data Monitoring Committee ...................................................69
10.1.6. Dissemination of Clinical Study Data ......................................................70
10.1.7. Data Quality Assurance ............................................................................71
10.1.8. Source Documents....................................................................................72
10.1.9. Use of Medical Records............................................................................72
10.1.10. Study and Site Start and Closure ............................................................73


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 8
10.1.11. Publication Policy...................................................................................74
10.1.12. Sponsor’s Medically Qualified Individual..............................................74
10.2. Appendix 2: Clinical Laboratory Tests .................................................................76
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting .....................................................................78
10.3.1. Definition of AE .......................................................................................78
10.3.2. Definition of an SAE ................................................................................79
10.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During 
the Active Collection Period............................................................................80
10.3.4. Reporting of SAEs....................................................................................84
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................85
10.4.1. Male Participant Reproductive Inclusion Criteria....................................85
10.4.2. Female Participant Reproductive Inclusion Criteria.................................85
10.4.3. Woman of Childbearing Potential ............................................................86
10.4.4. Contraception Methods.............................................................................87
10.5. Appendix 5: Liver Safety: Suggested Actions and Follow-Up Assessments .......89
10.6. Appendix 6: Kidney Safety: Monitoring Guidelines ............................................91
10.6.1. Laboratory Assessment of Change in Kidney Function and 
Detection of Kidney Injury..............................................................................91
10.6.2. Age-Specific Kidney Function Calculation Recommendations...............91
10.6.2.1. Adults (18 Years and Above)—2021 CKD-EPI 
Equations ...........................................................................................91
10.6.3. Kidney Function Calculation Tool ...........................................................92
10.6.4. Adverse Event Grading for Kidney Safety Laboratory 
Abnormalities...................................................................................................92
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................94
10.8. Appendix 8: Prohibited Concomitant Medications That May Result in DDI.......96
10.9. Appendix 9: AEs, ADEs, SAEs, SADEs, USADEs, and Device 
Deficiencies: Definitions and Procedures for Recording, Evaluating, 
Follow-Up, and Reporting in Medical Device Studies .............................................97
10.9.1. Definition of AE and ADE .......................................................................97
10.9.2. Definition of SAE, SADE, and USADE ..................................................97
10.9.3. Definition of Device Deficiency...............................................................98


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 9
10.9.4. Recording/Reporting and Follow-Up of Medical Device 
Deficiencies......................................................................................................98
10.9.5. Reporting of SAEs..................................................................................100
10.9.6. Reporting of SADEs...............................................................................100
10.10. Appendix 10: Abbreviations .............................................................................101
11. REFERENCES ................................................................................................................105
LIST OF TABLES
Table 1.
Study Schedule of Assessment.................................................................18
Table 2.
Plasma Etrasimod PK Parameters Definitions .........................................64
Table 3.
Expected Width of 90% Confidence Interval for Different Possible 
Estimated Effects and Parameters of Interest...........................................66
Table 4.
Protocol Required Laboratory Assessments.............................................76


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 10
1. PROTOCOL SUMMARY 
1.1. Synopsis 
Protocol Title: 
A Phase 1, Open-Label, Single Dose, Fixed-Sequence Crossover Sub Study to Determine the 
Pharmacokinetics Using Tasso Device and Safety and Tolerability Using Wearable 
Monitoring Devices Following Single Oral Doses of Etrasimod 2 mg IR Tablets in Healthy 
Adult Participants in a Hybrid Decentralized Clinical Trial Design
Brief Title:
A Sub Study to Learn About the Study Medication Called Etrasimod Tablets in a Hybrid 
Decentralized Clinical Trial Setting
Regulatory Agency Identification Number(s):
US IND Number:
125154
EudraCT/EU CT Number:
2023-508119-22-00
ClinicalTrials.gov ID:
Not applicable
Pediatric Investigational Plan Number:
Not applicable
Protocol Number:
C5041050
Phase:
1
Rationale:
This sub study is being conducted to assess the feasibility of conducting a Phase 1 etrasimod 
study as a hybrid decentralized clinical trial with dosing by study personnel at the CRU and 
remote collection of PK, safety and tolerability data. The specific objectives of the sub study 
are to determine the pharmacokinetics (PK) and to assess the safety and tolerability of 
etrasimod clinical immediate release (IR) tablets 2 mg under fasted conditions in healthy 
adult participants in a hybrid decentralized clinical trial (DCT) design.
This study is being conducted under the main study C5041034 as a sub study for the 
following reasons. The assessments and the objectives of this study are distinctly different 
from the main study; however, the analysis plan of the sub study includes comparison of the 
results of the sub study conducted as a hybrid DCT design with corresponding results of the 
main study conducted at the CRU.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 11
Objectives and Endpoints:
Objectives
Endpoints
Primary: 
Primary:
To compare the PK of etrasimod 2 mg clinical IR 
tablets under fasted conditions in healthy participants 
using Tasso PK micro samples taken by participants
only (Treatment G) vs. CRU staff and participants 
(Treatment F) in a hybrid DCT design
Plasma AUC24 hr, AUC24hr-last, AUCinf (if data 
permit, otherwise AUClast) and Cmax of etrasimod
Secondary: 
Secondary:
To compare the PK of etrasimod 2 mg clinical IR 
tablets under fasted conditions in healthy participants 
using Tasso PK micro samples taken by participants 
only (Treatment G) vs. CRU staff and participants 
(Treatment F) in a hybrid DCT design vs. venous PK 
samples taken by CRU staff in conventional design of 
main study (Treatment A) 
Plasma AUC24 hr, AUC24hr-last, AUCinf (if data 
permit, otherwise AUClast) and Cmax of etrasimod
To evaluate the safety and tolerability of etrasimod 
2 mg clinical IR tablets in healthy participants using 
mobile wearable devices in a hybrid DCT design
Assessment of first dose HR reduction, TEAEs, 
clinical laboratory abnormalities, vital signs, 
PEs, and ECGs
Abbreviations: AUC24hr = area under the plasma concentration-time profile from time zero to 24 hr; AUC24hr-
last = area under the plasma concentration-time profile from time 24 hr to the time of the last quantifiable 
concentration; AUCinf = area under the concentration-time curve from time zero extrapolated to infinity; 
AUClast = area under the plasma concentration-time profile from time zero to the time of the last quantifiable 
concentration; Cmax = maximum observed concentration; DCT = decentralized clinical trial; CRU = Clinical 
Research Unit; ECG = electrocardiogram; HR = heart rate; IR = immediate release; PE = physical 
examination; PK = pharmacokinetic(s); TEAE = treatment emergent adverse event.
Overall Design:
This is a Phase 1, open-label, single-dose, fixed-sequence, crossover sub study in a single 
cohort of approximately 8 healthy male or female participants conducted using a hybrid DCT 
design. 
The study will consist of 2 treatments. Participants will receive the two Treatments F and G 
in a fixed sequence as shown below.
Fixed Treatment
Sequence (n=8)
Period 1
Period 2
F
G
Treatment F: Single oral dose of etrasimod 2 mg, DCT with practice sessions* (Reference)
Treatment G: Single oral dose of etrasimod 2 mg, DCT without practice sessions** (Test)
* Practice of Tasso and Wearable Monitoring Devices on Day 2 at CRU; participant self-assessment remotely for vitals 
and ECG (Days 3-5) and PK samples (Days 3-8)
** Participant self-assessment using Tasso and Wearable Monitoring Devices on Days 1-2 at CRU; and remotely on 
Days 3-8 
Following are the key elements of the design of this hybrid decentralized clinical trial. 
Participants will be discharged from the clinical research unit (CRU) on Day 2 of each 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 12
Period, following practice sessions (Period 1 only) with the use of Tasso for serum PK 
sampling and wearable devices for safety monitoring, and the completion of all assessments 
that are planned to be performed at the CRU. The Tasso OnePlus, high-volume liquid blood 
collection device, will be used for micro-PK sampling and the blood samples collected by 
participants will be sent to the CRU within 72 hours of collection for processing of serum.
The BioBeat Patch and PCA500 wearable monitoring devices will be used for collection of 
vitals and ECGs, respectively, in Periods 1 and 2. Each treatment period is 8 days that 
includes dosing, PK sampling, safety assessments, and practice (Period 1 only) with use of 
wearable devices and Tasso sampling. The PK and safety (ECGs and vitals) assessments 
through Day 2 of Period 1 will be performed by the CRU staff. Following practice with the 
Tasso and wearable monitoring devices on Day 2 of Period 1, the assessments on Days 3 to 8 
(remote) of Period 1 and on Days -1 to 2 (at CRU) and 3 to 8 (remote) of Period 2 will be 
self-performed by the participants. Participants will be discharged from the CRU on Day 2 of 
Periods 1 and 2. Participants will receive an emergency card for contacting the CRU and will 
be provided detailed instructions to call PCRU for reporting of an AE. Additionally, the 
participants will be provided with diaries to record information about PK sampling times,
concomitant medication(s) and AEs during the self-assessment phase following discharge on 
Day 2 of Periods 1 and 2. The participants will be provided instructions for returning the 
wearable devices and other study related materials study following completion of all 
assessments on Day 8 of Period 2. The total planned duration of participation from the 
screening visit to the last follow-up phone call, is approximately 9 weeks.
Number of Participants:
A total of 8 participants will be assigned to study intervention in a fixed sequence of two 
single-dose treatments. 
Participants who withdraw from the study or whose study data are determined to be 
non-analyzable may be replaced at the discretion of the investigator upon consultation with 
the sponsor.
Note: “Enrolled” means a participant’s agreement to participate in a clinical study following 
completion of the informed consent process and randomization to study intervention. 
Study Population:
Key inclusion and exclusion criteria are listed below:
Inclusion Criteria 
Participants must meet the following key inclusion criteria to be eligible for enrollment into 
the study:
1.
Male and female participants aged 18 years or older (or the minimum age of consent 
in accordance with local regulations) at screening who are overtly healthy as 
determined by medical evaluation including a detailed medical history, full physical 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 13
exam, which includes blood pressure (BP) and pulse rate measurement, clinical 
laboratory tests, temperature, and 12-lead ECG.
2.
Body mass index (BMI) of 16 to 32 kg/m2; and a total body weight >50 kg (110 lb).
3.
Participants who are willing and able to comply with all scheduled visits, treatment
plan, laboratory tests, lifestyle considerations, and other study procedures.
4.
Capable of giving signed informed consent.
Exclusion Criteria 
Participants with any of the following characteristics/conditions will be excluded:
1. Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, 
anaphylactic, ophthalmologic disorder (such as macular edema, uveitis, retinopathy), 
or allergic disease.
2. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
3. Known immunodeficiency disorder, including positive serology for human 
immunodeficiency virus (HIV), or a first degree relative with a hereditary 
immunodeficiency.
4. Infection with hepatitis B or hepatitis C viruses according to protocol specific testing
algorithm history.
5. Participants with any of the specified acute or chronic infections or infection history.
6. History of febrile illness within 5 days prior to the first dose of study intervention.
7. History of any lymphoproliferative disorder such as Epstein-Barr virus (EBV) related 
lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs or 
symptoms suggestive of current lymphatic or lymphoid disease.
8. Known present or a history of malignancy other than a successfully treated or excised
nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in
situ.
9. Evidence of untreated or inadequately treated active or latent Mycobacterium 
tuberculosis (TB) infection.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 14
Study Arms and Duration:
Participants will receive a single dose of etrasimod 2 mg on Day 1 of each period. The total 
planned duration of participation from the screening visit to the last follow-up phone call, is 
approximately 9 weeks.
Study Intervention(s)
Intervention Name
Etrasimod clinical IR tablets, 2 mg
Reference product
Use
Experimental
IMP or NIMP/AxMP
IMP
Dose Formulation
Coated tablets containing 2 mg etrasimod each
Unit Dose Strength(s)
2 mg/tablet
Route of 
Administration
Oral
Abbreviations: AxMP = auxiliary medicinal product; IMP = investigational medicinal product; IR = immediate release; 
NIMP = noninvestigational medicinal product.
Study Arm(s)
Arm Title
Period 1
Period 2
Arm Description
Participants will receive a single dose of etrasimod on Day 1 of each period. 
Participants will be assigned to a fixed crossover sequence to receive single-dose 
Treatments F and G in Periods 1 and 2, respectively. 
In each period, etrasimod 2 mg clinical IR tablet will be administered with 240 mL 
water under fasting conditions.
Etrasimod will be supplied as clinical IR tablet to the CRU in bulk in high-density 
polyethylene (HDPE) bottles. 
Statistical Methods:
Sample Size Estimation
A sample size of 8 participants will provide adequate precision to estimate the relative 
bioavailability (rBA) of etrasimod across studies. These estimates are based on the 
assumption that standard deviations are 0.281 and 0.305 for lnAUCinf and lnCmax, 
respectively, as obtained from studies APD334-007 and APD334-114. 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 15
Primary Endpoints
PK parameters will be summarized descriptively by treatment, in accordance with Pfizer data 
standards. Plasma concentrations will be listed and summarized descriptively by nominal PK 
sampling time and treatment. Individual participant and median profiles of the plasma 
concentration-time data will be plotted by treatment using actual and nominal times, 
respectively. Median profiles will be presented on both linear-linear and log-linear scales.
Natural log transformed AUC24hr, AUC24hr-last, AUCinf, AUClast, and Cmax will be analyzed using 
a mixed effect model with treatment as fixed effect and participant within the sequence as a 
random effect. Treatment F (etrasimod 2 mg, DCT Tasso PK micro samples taken by CRU 
staff and participants) will be the Reference treatment while Treatment G (etrasimod 2 mg, 
DCT Tasso PK micro samples taken by participants only) will be the Test treatment.
Additionally, natural log transformed AUC24hr, AUC24hr-last, AUCinf, AUClast, and Cmax will be 
analyzed using a mixed effect model with treatment as a fixed effect. Treatment A (etrasimod 
2 mg, Main study, venous PK samples) will be the Reference treatment while Treatment F 
(etrasimod 2 mg, DCT Tasso PK micro samples taken by CRU staff and participants) and 
Treatment G (etrasimod 2 mg, DCT Tasso PK micro samples taken by participants only) will 
be the Test treatments.
Secondary Endpoints
AEs, ECGs, BP, pulse rate, and safety laboratory data will be reviewed and summarized on 
an ongoing basis during the study to evaluate the safety of participants. Any clinical 
laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be 
described. Safety data will be presented in tabular and/or graphical format and summarized 
descriptively, where appropriate.
Ethical Considerations:
Etrasimod, an investigational, oral, and once daily sphingosine 1-phosphate (S1P) receptor 
modulator, is not expected to provide any clinical benefit to healthy participants. In this 
study, etrasimod will be administered as a single dose of 2 mg in each period of the study. 
The sub study is being conducted to assess the feasibility of conducting a Phase 1 etrasimod 
study as a hybrid decentralized clinical trial 1,2 with dosing by study personnel at the CRU 
and remote collection of PK, safety and tolerability data. DCTs have the potential to expand 
                                                
1 FDA. Decentralized clinical trials for drugs, biological products, and devices. May 2023. Available 
from: Decentralized Clinical Trials for Drugs, Biological Products, and Devices | FDA. Accessed: 09 Aug 2023.
2 EMA. Recommendation paper on decentralised elements in clinical trials. Version 01, 13 Dec 2022. 
Available from: mp_decentralised-elements_clinical-trials_rec_en.pdf (europa.eu). Accessed: 09 Aug 2023.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 16
access to more diverse patient populations and improve trial efficiencies. 3 Advances in 
clinical care using electronic communications and information technology to interact with 
trial participants in different locations (ie, telehealth) allow for fewer in-person visits to 
clinical trial sites. Digital health technologies (DHTs), for example, have expanded the types 
of trial-related data that can be obtained remotely from trial participants. By enabling remote 
participation, DCTs may enhance convenience for trial participants, reduce the burden on 
caregivers, and facilitate research on rare diseases and diseases affecting populations with 
limited mobility or access to traditional trial sites. This may help improve trial participant 
engagement, recruitment, enrollment, and retention of a meaningfully diverse clinical 
population.
Etrasimod 2 mg was determined to be well tolerated and to have an acceptable safety profile 
in both healthy participant and diseased clinical studies.
Participants will be expected to commit time and may experience some discomfort while 
undergoing study assessments. In addition, participants of childbearing potential must agree 
to use appropriate contraception methods. Participants should avoid vaccination with live 
attenuated replication-competent vaccines. It is recommended that participants keep their diet 
habits constant throughout the study.
                                                
3 FDA. Guidance for industry: enhancing the diversity of clinical trial populations - eligibility criteria, 
enrollment practices, and trial designs. November 2020. Available from: Enhancing the Diversity of Clinical 
Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry | FDA. 
Accessed: 09 Aug 2023.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 17
1.2. Schema


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 18
1.3. Schedule of Activities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evaluations or 
assessments required to protect the well-being of the participant.
Table 1.
Study Schedule of Assessment
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 10
Screen
Periods 1-2
F/U
Telephone 
Contact
ET
Notes
Days Relative to Day 1 in Each 
Period
Day -28 
to 
Day -2
Day
-1
Day
1
Day
2
Days
3-8
Days 
28-35*

Participants will be screened within 28 days of the 
first dose of study intervention.

* Follow-up contact will occur by telephone and 
must occur at least 28 to 35 days after the last 
administration of etrasimod (Day 1 of Period 2 if 
dosing completed).
Period 1 Study Days
-28 to -2
-1
1
2
3-8
Participants will be discharged from CRU on 
Day 2 of Period 1
Period 2 Study Days
9
10
11
12-17

Minimum 8-day washout period between dosing 
in Periods 1 and 2

Participants will be discharged from CRU on 
Day 2 of Period 2.
Check In
X
Informed consent
X
Inclusion/exclusion criteria
X
X

Inclusion/exclusion criteria should be reviewed 
and updated on Day -1 of Period 1 only.
CRU confinement
X


Participants will be discharged from CRU on 
Day 2 of Periods 1 and 2
Demography
X

Including measurement of height and weight
Medical/medication history, drug, 
tobacco, and alcohol history
X
X

Include history of alcohol abuse, tobacco/nicotine 
containing products, licit and illicit drug use or 
dependence within 6 months of screening. 

For Day -1, records should be reviewed or updated 
only.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 19
Table 1.
Study Schedule of Assessment
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 10
Screen
Periods 1-2
F/U
Telephone 
Contact
ET
Notes
Days Relative to Day 1 in Each 
Period
Day -28 
to 
Day -2
Day
-1
Day
1
Day
2
Days
3-8
Days 
28-35*

Participants will be screened within 28 days of the 
first dose of study intervention.

* Follow-up contact will occur by telephone and 
must occur at least 28 to 35 days after the last 
administration of etrasimod (Day 1 of Period 2 if 
dosing completed).
Period 1 Study Days
-28 to -2
-1
1
2
3-8
Participants will be discharged from CRU on 
Day 2 of Period 1
Period 2 Study Days
9
10
11
12-17

Minimum 8-day washout period between dosing 
in Periods 1 and 2

Participants will be discharged from CRU on 
Day 2 of Period 2.
Physical exam
X
X

See Section 8.3.1

Must be conducted at screening or upon admission 
on Day -1 Period 1 only.
Ophthalmology exam
X

See Section 8.3.1

Further ophthalmologic assessment will be 
arranged for any ophthalmic adverse event 
throughout the trial
Safety laboratory
X
X
X
X
Safety laboratory screening testing must be 
collected, reported, and reviewed within 28 days 
prior to first administration of study intervention. 

Safety laboratory assessments including urinalysis, 
hematology, and chemistry will be performed. 
Participants should fast for at least 4 hours prior to 
any safety blood collection. Additional laboratory 
assessments may be performed if deemed 
necessary by the investigator. 

If labs are not within normal range on Day 2 of 
Period 2, unscheduled follow-up visits will occur 
per protocol.

Refer to Table 4 for full list of assessments 
Urine drug testing
X
X
Pregnancy test (WOCBP only)
X
X

See Table 4 for more details.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 20
Table 1.
Study Schedule of Assessment
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 10
Screen
Periods 1-2
F/U
Telephone 
Contact
ET
Notes
Days Relative to Day 1 in Each 
Period
Day -28 
to 
Day -2
Day
-1
Day
1
Day
2
Days
3-8
Days 
28-35*

Participants will be screened within 28 days of the 
first dose of study intervention.

* Follow-up contact will occur by telephone and 
must occur at least 28 to 35 days after the last 
administration of etrasimod (Day 1 of Period 2 if 
dosing completed).
Period 1 Study Days
-28 to -2
-1
1
2
3-8
Participants will be discharged from CRU on 
Day 2 of Period 1
Period 2 Study Days
9
10
11
12-17

Minimum 8-day washout period between dosing 
in Periods 1 and 2

Participants will be discharged from CRU on 
Day 2 of Period 2.
Contraception check
X
X
X
X
X

The contraception check is to confirm that 
contraception, if applicable, is used consistently 
and correctly.
12-Lead ECG
X
X
X
X
X

Assessments using standard ECG machine at
screening.

Assessments using wearable device for Periods 1 
and 2.

On Day 1 of each period perform ECGs 
pre-etrasimod dose and every hour up to 6 hours, 
and at 8 and 24 hours post-etrasimod dose (in 
Period 1 by staff and in Period 2 by participants). 
The pre-etrasimod dose ECGs will be done in 
triplicate. 

On Days 3-5 of each period, perform ECGs at 
approximately the same clock time as etrasimod 
dose on Day 1 (in both Periods by participants).

Refer to Section 8.3.3 for additional details
Blood pressure, pulse rate, 
temperature 
X
X
X
X
X

Assessments using standard methodology (BP, PR 
and temperature) at screening.

Assessments using standard methodology
(temperature) in Periods 1 and 2.
o
Temperature will only be performed predose
on Day 1. 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 21
Table 1.
Study Schedule of Assessment
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 10
Screen
Periods 1-2
F/U
Telephone 
Contact
ET
Notes
Days Relative to Day 1 in Each 
Period
Day -28 
to 
Day -2
Day
-1
Day
1
Day
2
Days
3-8
Days 
28-35*

Participants will be screened within 28 days of the 
first dose of study intervention.

* Follow-up contact will occur by telephone and 
must occur at least 28 to 35 days after the last 
administration of etrasimod (Day 1 of Period 2 if 
dosing completed).
Period 1 Study Days
-28 to -2
-1
1
2
3-8
Participants will be discharged from CRU on 
Day 2 of Period 1
Period 2 Study Days
9
10
11
12-17

Minimum 8-day washout period between dosing 
in Periods 1 and 2

Participants will be discharged from CRU on 
Day 2 of Period 2.

Assessments using wearable device (BP, PR) in 
Periods 1 and 2.
o
On Day 1 of each period PR and BP vital 
signs will be performed at predose (baseline) 
and every hour up to 6 hours, and at 8 and 24 
hours post-etrasimod dose (in Period 1 by 
CRU staff and in Period 2 by participants). 
o
On Days 3-5 of each period, PR and BP will 
be taken at approximately the same clock 
time as etrasimod dose on Day 1 (in both 
Periods by participants).

ECG will be taken first followed by vital signs. 
HIV, HbsAg, HbcAb, HbsAb, 
HCVAb
X

If HbsAg is negative and HbcAb is positive, 
HbsAb should be evaluated.
COVID-19 related procedures
X

Performed per local procedures
TB (QuantiFERON® Gold Test)
X
Study intervention administration
X

Participants assigned to receive study intervention 
under fasted must be fasted for at least 10 hours 
pre dosing and 4 hours postdosing.

See Section 6.1.1 for additional details


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 22
Table 1.
Study Schedule of Assessment
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 10
Screen
Periods 1-2
F/U
Telephone 
Contact
ET
Notes
Days Relative to Day 1 in Each 
Period
Day -28 
to 
Day -2
Day
-1
Day
1
Day
2
Days
3-8
Days 
28-35*

Participants will be screened within 28 days of the 
first dose of study intervention.

* Follow-up contact will occur by telephone and 
must occur at least 28 to 35 days after the last 
administration of etrasimod (Day 1 of Period 2 if 
dosing completed).
Period 1 Study Days
-28 to -2
-1
1
2
3-8
Participants will be discharged from CRU on 
Day 2 of Period 1
Period 2 Study Days
9
10
11
12-17

Minimum 8-day washout period between dosing 
in Periods 1 and 2

Participants will be discharged from CRU on 
Day 2 of Period 2.
PK blood sampling (Periods 1 and 
2)
X
X

Venous PK sample blood collection (for Tasso 
results comparison) will be at the following 
timepoints: predose and at 2 and 4 hours postdose.
PK micro sampling (Periods 1 and 
2)
X
X
X

Micro sampling PK sample collection will be on 
the day of dosing at the following timepoints: 
predose and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 
144, and 168 hours postdose

Micro PK sampling for Period 1 (Treatment F) 
will be performed by CRU staff up to 24 hours 
postdose (at CRU) and by the participants 48-168 
hours post dose (remote)

Micro PK sampling for Period 2 (Treatment G) 
will be performed by the participants at the CRU 
(up to 24 hours postdose) and remote (48-168 
hours postdose)

Micro PK sampling occurs after venous PK blood 
sampling; samples to be taken from the alternate 
arms from one sampling time to the next.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 23
Table 1.
Study Schedule of Assessment
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 10
Screen
Periods 1-2
F/U
Telephone 
Contact
ET
Notes
Days Relative to Day 1 in Each 
Period
Day -28 
to 
Day -2
Day
-1
Day
1
Day
2
Days
3-8
Days 
28-35*

Participants will be screened within 28 days of the 
first dose of study intervention.

* Follow-up contact will occur by telephone and 
must occur at least 28 to 35 days after the last 
administration of etrasimod (Day 1 of Period 2 if 
dosing completed).
Period 1 Study Days
-28 to -2
-1
1
2
3-8
Participants will be discharged from CRU on 
Day 2 of Period 1
Period 2 Study Days
9
10
11
12-17

Minimum 8-day washout period between dosing 
in Periods 1 and 2

Participants will be discharged from CRU on 
Day 2 of Period 2.
CRU discharge
X

The participants will be discharged on Day 2 of 
each Period.
Participant Training for Micro PK 
Sampling, and Wearable 
Monitoring Devices, and recording 
of PK sampling times, concomitant 
medications and AEs 


X#


# On Day 2 of Period 1, prior to discharge, 
participants will be trained on 1) use of devices 
(PCA500, BioBeat and Tasso) and provided with 
instruction materials for self-assessment of 
ECGs, vitals and PK samples, and 2) completion 
of diaries to record PK sampling times, 
concomitant medications and AEs

In both Periods, participants will be provided 
with adequate supply of devices and diaries for 
remote self-assessment following discharge on 
Day 2
Serious and nonserious AE 
monitoring
X




X
X

See Section 8.4.3 for follow up AE and SAE 
assessments.

AEs during Days 3-8 of both study Periods will 
be recorded on CRF by participants and if 
needed, reported to CRU by telephone.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 24
2. INTRODUCTION
Etrasimod is an orally administered, selective, synthetic S1P1,4,5 modulator that is being 
developed to treat immune-mediated inflammatory disorders, including UC, AA, AD, and 
EoE. The S1P1 is a cell surface expressed protein that has been shown to regulate lymphocyte 
migration out of lymphoid tissues. Synthetic small molecule S1P1 agonists have been 
observed to act as functional antagonists by inducing sustained receptor internalization, thus 
inhibiting lymphocyte migration out of lymphoid tissues and lowering the amount of 
peripheral blood lymphocytes available to be recruited to sites of inflammation. Modulation 
of the S1P/S1P receptor axis is thought to be a potential therapeutic approach to the 
management of immune-mediated inflammatory disorders.
2.1. Study Rationale 
This sub study is being conducted to assess the feasibility of conducting a Phase 1 etrasimod 
study as a hybrid decentralized clinical trial with dosing by study personnel at the CRU and 
remote collection of PK, safety and tolerability data. The specific objectives of the sub study 
are to determine the PK and to assess the safety and tolerability of etrasimod clinical IR 
tablets 2 mg under fasted conditions in healthy adult participants in a hybrid DCT design.
This study is being conducted under the main study C5041034 as a sub study for the 
following reasons. The assessments and the objectives of this study are distinctly different 
from the main study; however, the analysis plan of the sub study includes comparison of the 
results of the sub study conducted as a hybrid DCT design with corresponding results of the 
main study conducted at the CRU.
2.2. Background 
The pharmacology, safety pharmacology, PK, metabolism, toxicology and clinical 
dose-ranging efficacy and safety of etrasimod oral administration had been comprehensively 
studied. A summary of relevant, currently available data is provided in this protocol. 
Additional details and further information for this compound could be found in the current 
IB.
The sub study is being conducted to assess the feasibility of conducting a Phase 1 etrasimod 
study as a hybrid decentralized clinical trial 1,2 with dosing by study personnel at the CRU 
and remote collection of PK, safety and tolerability data. DCTs have the potential to expand 
access to more diverse patient populations and improve trial efficiencies.3 Advances in 
clinical care using electronic communications and information technology to interact with 
trial participants in different locations (ie, telehealth) allow for fewer in-person visits to 
clinical trial sites. DHTs, for example, have expanded the types of trial-related data that can 
be obtained remotely from trial participants. By enabling remote participation, DCTs may 
enhance convenience for trial participants, reduce the burden on caregivers, and facilitate 
research on rare diseases and diseases affecting populations with limited mobility or access 
to traditional trial sites. This may help improve trial participant engagement, recruitment, 
enrollment, and retention of a meaningfully diverse clinical population.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 25
2.2.1. Nonclinical Pharmacology
A summary of the nonclinical investigational programs can be found in the current IB.
2.2.2. Nonclinical Pharmacokinetics and Metabolism
Etrasimod is eliminated primarily hepatically by extensive metabolism involving oxidation of 
etrasimod, along with dehydrogenation and conjugation, and showed no human specific 
metabolite(s) compared to those observed in the toxicology species. The main CYP enzymes 
involved in the oxidative metabolism of etrasimod are CYP2C8 (38%), CYP2C9 (37%), and 
CYP3A4 (22%), and with CYP2C19 and CYP2J2 being minor contributors (1% each). There 
are no major circulating metabolites and etrasimod is the primary circulating drug entity.
Additional information of the nonclinical PK and metabolism of etrasimod is available in the 
current IB.
2.2.3. Nonclinical Safety
Etrasimod was well tolerated across the general toxicity program conducted in CD-1 mice,
Sprague Dawley rats, and beagle dogs, with no etrasimod-induced mortality following repeat
administration up to 91-days, 6-months, and 9-months at 20, 150, and 15 mg/kg/day in mice,
rats, and dogs, respectively.  Most etrasimod-related findings were considered nonadverse,
reversible upon cessation of treatment, and/or readily monitorable in the clinic. One of the 
most common adverse effects across species was decreased body weight and/or body weight 
gain, with associated decreases in food consumption. The primary target organs identified 
across all species were lymphoid tissues, lung, and liver. In addition, the heart was identified 
as a target organ in the dog. When administered at doses within and above the therapeutic 
range (up to 858 × in rats and 380 × in dogs over the total Cmax exposure at the proposed 
human dose for the treatment of UC) in safety pharmacology studies, etrasimod showed no 
effect on CNS, respiratory, or cardiovascular function.
The potential effects of etrasimod on the cardiovascular system were investigated in a series 
of in vitro and in vivo studies. In vitro, etrasimod increased hERG currents by 31.4% at 1 
mm and 58.9% at 3 mm. These concentrations are approximately 193 × and 578 × over the 
free Cmax exposure at the proposed human dose for the treatment of UC. An IC50 for hERG
current inhibition could not be established for etrasimod since only increases in hERG
channel current, rather than inhibition, were observed.  Based on the G protein receptor 
signaling associated with the primary PD activity, etrasimod was observed to activate GIRK 
currents in vitro. GIRK1 and GIRK4 are the 2 homologous subunits of IκACh that interact with 
Gβγ to mediate the activation of the potassium channel.4 G-protein signaling via GIRK IκACh 
channel activation in cardiac cells is considered to be responsible for the transient 
cardiovascular effects seen with first dose of S1P receptor modulators.5, 6, 7 At IκACh in 
primary human atrial cardiomyocytes, etrasimod exhibited an EC50 of 29.9 nM and there was 
no difference between S1P and etrasimod in the time course of IκACh activation. The maximal 
current induced by etrasimod, however, was 90% of that observed with carbachol and was 
10 × lower (based on EC50) than S1P itself.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 26
Etrasimod was not mutagenic or clastogenic in in vitro genetic toxicity studies and is not 
considered genotoxic in rats or to pose a genotoxic risk to humans. There were no etrasimod-
related effects on spermatogenesis or fertility in males at any dose level evaluated. In the 
embryo-fetal development studies in rats and rabbits, administration of etrasimod during the 
period of organogenesis resulted in increased post implantation loss and decreased mean 
litter numbers and proportions of viable fetuses in both species. The embryo lethality and 
fetal malformations noted with etrasimod in the rat and rabbit embryo-fetal development 
studies are consistent with similar findings observed with approved S1P modulators8, 9, 10, 11
and are believed to be a result of the important role of S1P1 in embryogenesis, including 
vascular and neural development.12
Further details of the nonclinical safety program are provided in the current IB.
2.2.4. Clinical Overview
Safety, tolerability and PK of etrasimod were evaluated in 15 Phase 1 studies in healthy adult
participants. Efficacy and safety of etrasimod was evaluated in 3 completed Phase 2, 
6 ongoing Phase 2, 4 completed Phase 3 and 1 ongoing Phase 3 studies across several disease 
indications. Clinical pharmacology data established the PK properties of etrasimod with or 
without food and in specified participant subpopulations (eg, participants with renal or 
hepatic impairment), and included comprehensive drug interaction studies to inform dosing 
recommendations.
A complete summary of the clinical data relevant to etrasimod and its study in human 
participants is provided in the current edition of the IB.
2.2.4.1. Pharmacokinetic Overview of Etrasimod
Etrasimod is absorbed with a median Tmax of 4 hours after administration as an etrasimod 
2 mg IR tablet in the fasted state, and up to 6 hours in the fed state. Food did not affect 
etrasimod exposure measures (Cmax and AUC). Plasma Cmax and AUC values of etrasimod 
are dose proportional following a single dose of 0.1 to 5 mg. For multiple-doses of etrasimod 
over a range of 0.7 to 2 mg once daily, steady-state Cmax increased dose proportionally and 
steady-state AUC0-24 increased slightly greater than dose proportionally. Apparent dose
proportional increases were also observed for mean steady-state Cmax and AUC0-24 values 
from 2 to 4 mg once daily dosing in healthy participants. The time to reach approximate 
steady-state for etrasimod exposure measures (Cmax, AUC0-24, Ctrough) is within 7 days of the 
first dose. Mean Rac for etrasimod exposure measures are <3-fold with once daily dosing. 
These observations are consistent with etrasimod’s elimination (effective) half-life of 
approximately 30 hours. The mean oral Vz/F of etrasimod ranged from 50 to 103 L in healthy 
participants across evaluated single and multiple-dose levels and Phase 1 studies, indicating 
extravascular distribution. The mean oral plasma CL/F of etrasimod following single and 
multiple-dose administration of etrasimod was low and ranged from 1.13 to 1.43 L/h and 
0.97 to 1.70 L/h, respectively, in healthy participants across evaluated dose levels in the
Phase 1 studies.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 27
The human mass balance study identified 2 oxidative metabolites, AR503641 (M3) and
AR504344 (M6) present in systemic circulation, though minor as they are each <10% of total
radioactivity. The oxidation of etrasimod occurs by 3 CYPs (CYP2C8, CYP2C9 and 
CYP3A4). Etrasimod is primarily eliminated in feces, with no parent drug detected in the 
urine. 
2.2.4.2. Safety Overview of Etrasimod
As of 30 Aug 2022, a total of 2119 participants (419 healthy participants and 1700 
participants with disease) have been exposed to etrasimod in clinical development programs.  
Clinical evidence in participants of healthy status, UC, CD, AD, AA or EoE to date have 
demonstrated that etrasimod is well tolerated in humans. 
Across all clinical studies (Phase 1 to Phase 3), etrasimod caused expected mild, transient, 
and generally asymptomatic reduction in HR at first dose and very few participants with HR 
< 50 bpm. These reductions were greatest following first dose and lessened upon repeat 
dosing due to development of tolerance, allowing HR to return to baseline. The HR effects 
are related to S1P1 localized on atrial myocytes that activate GIRK channels, which are 
transient and not clinically adverse or associated with safety findings.
Etrasimod 2 mg administered once daily demonstrated an acceptable safety profile up to
52 weeks in controlled studies and up to 104 weeks in uncontrolled studies. There was a low
incidence of SDEIs such as infections, including severe (ie, Grade ≥3) infections, 
opportunistic infections, and herpes infections (herpes zoster and herpes simplex), cardiac 
safety events (bradycardia, AV conduction delays, and hypertension), malignancies, liver 
injury (liver transaminase elevation and bilirubin elevation), macular oedema, and pulmonary 
disorders (airflow obstruction and decreased gas exchange) in participants who were treated 
with etrasimod 2 mg.
2.3. Benefit/Risk Assessment
Etrasimod, an investigational, oral, and once daily S1P receptor modulator, is not expected to 
provide any clinical benefit to healthy participants. In this study, etrasimod will be 
administered at single doses of 2 mg. This study is being conducted primarily to generate 
safety, tolerability, pharmacokinetic data for the etrasimod tablets in a hybrid DCT design. 
Etrasimod was determined to be well tolerated and to have an acceptable safety profile in 
both healthy participant and diseased clinical studies. 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of etrasimod may be found in the IB, which is the SRSD for this study. Refer 
to the Study Intervention(s) table in Section 6.1 for a complete description of SRSDs.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 28
2.3.1. Risk Assessment
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
Study Intervention(s) Etrasimod
S1P receptor modulator-related effects (class 
effect of AEs observed with S1P receptor 
modulators) may be observed.

cardiovascular events (eg, bradycardia, 
atrioventricular conduction delay and 
hypertension)

infections (severe infections, 
opportunistic infections, Herpes simples 
and Herpes zoster)

macular edema 

pulmonary events (airflow obstruction or 
altered gas exchange)

liver injury

malignancy
Clinical experience with other S1P receptor 
modulators for the treatment of MS and UC.  

The totality of etrasimod clinical studies 
(Phase 1, 2 and 3 studies) have shown that 
2 mg etrasimod is well-tolerated with no 
clinically significant safety signals.
Exclusion of participants at risk. Short duration of 
treatment. Safety labs at screening and baseline
and when deemed necessary by the investigator
throughout the study. AE monitoring throughout 
the study.
S1P receptor modulator-specific lymphocyte level 
decreases.
Dose-dependent reductions in peripheral
lymphocyte counts are an expected PD effect of 
etrasimod.
The totality of clinical studies following single 
dose administration of study intervention is 
well-tolerated with a return to normal range by 
Day 7.
Participants with conditions or risk factors related 
to infection or immune function will be excluded 
from the study.
Participants will be assessed for safety including 
infections at regular intervals throughout the 
study to identify and mitigate the potential risks.
First dose cardiac effect
S1P receptor modulators class of drugs is 
associated with an expected, on-target effect of 
reducing HR when first dosed.
The totality of clinical data up to date across Phase 
1 to 3 studies across several indications indicate 
that etrasimod 2 mg is well-tolerated with modest 
Participants with elevated cardiac risk factors will 
be excluded from participation in the study.
Specifically, Section 5.2 Exclusion Criterion #1 is 
aligned with IB to require “Myocardial infarction, 
unstable angina, stroke/transient ischemic attack, 
decompensated heart failure requiring 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 29
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
HR reduction that is maximal on the first day of 
dosing without major clinically relevant cardiac 
safety events.
hospitalization, or Class III/IV heart failure ≤6 
months prior to study intervention.”  
Hourly HR monitoring for the first 6-hours post 
first dose will be conducted for all dose periods.
Participants with cardiac effects associated with
first dose will be required to permanently
discontinue study intervention.
Reproductive and developmental toxicity.
The effects of etrasimod on human fertility and
embryonic development are unknown. 
Nonclinical reproductive and developmental 
toxicity studies of etrasimod combined with data 
and knowledge on the role of S1P1 in vascular 
embryogenesis demonstrate embryo fetal toxicity 
of etrasimod if used during pregnancy.
Etrasimod is potentially teratogenic in humans with 
a low genotoxic potential.
There is no margin of safety for these findings
compared to therapeutic exposure range. Etrasimod 
should not be given to women who are pregnant, 
lactating, or breastfeeding.
WOCBP who are pregnant, lactating, or 
breastfeeding will be excluded from this study.
WOCBP will be eligible only if she and her
partner(s) agree(s) with the contraceptive method 
as described in Section 10.4.4 throughout the 
study period and for at least 28 days after the last 
dose of etrasimod.
Males with female partners of childbearing
potential must agree to use contraception
throughout the study period and for at least
28 days after the last dose of etrasimod.
Macular Edema.
Macular edema is an identified risk which requires 
specific ophthalmologic monitoring. 
In this study, an ophthalmologic examination by 
an ophthalmologist is included at baseline
(Screening) and for clinical monitoring of any 
signs or symptoms throughout the trial, as 
needed.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 30
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
Study Procedures Blood Collection for PK
Extravasation, bruising, local discomfort
Collection of 3 venous PK plasma samples each in 
Period 1 and 2.
Collection of 14 PK micro samples each in Periods 
1 and 2.
Use of highly qualified nurses, with venipuncture 
experience. 
Use of alternating arms for adjacent time points 
can provide more resting and healing time for 
each arm between samplings.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 31
2.3.2. Benefit Assessment
Etrasimod is not expected to provide any clinical benefit to healthy participants. This sub 
study is designed primarily to assess the feasibility of conducting a Phase 1 etrasimod study 
as a hybrid decentralized clinical trial with dosing by study personnel at the CRU and remote 
collection of PK, safety and tolerability data. In this study, etrasimod will be administered at
single doses of 2 mg.
2.3.3. Overall Benefit/Risk Conclusion
Taking into account the measures to minimize risk to study participants, the potential risks 
identified in association with etrasimod are justified by the anticipated benefits that may be 
afforded to participants with UC.
3. OBJECTIVES AND ENDPOINTS
Objectives
Endpoints
Primary: 
Primary: 
To compare the PK of etrasimod 2 mg clinical IR 
tablets under fasted conditions in healthy participants 
using Tasso PK micro samples taken by participants 
only (Treatment G) vs. CRU staff and participants 
(Treatment F) in a hybrid DCT design
Plasma AUC24 hr, AUC24hr-last, AUCinf (if data 
permit, otherwise AUClast) and Cmax of 
etrasimod
Secondary: 
Secondary: 
To compare the PK of etrasimod 2 mg clinical IR 
tablets under fasted conditions in healthy participants 
using Tasso PK micro samples taken by participants 
only (Treatment G) vs. CRU staff and participants 
(Treatment F) in a hybrid DCT design vs. venous PK 
samples taken by CRU staff in conventional design 
of main study (Treatment A) 
Plasma AUC24 hr, AUC24hr-last, AUCinf (if data 
permit, otherwise AUClast) and Cmax of 
etrasimod
To evaluate the safety and tolerability of etrasimod 
2 mg clinical IR tablets in healthy participants using 
mobile wearable devices in a hybrid DCT design
Assessment of first dose HR reduction, 
TEAEs, clinical laboratory abnormalities, vital 
signs, PEs, and ECGs
Tertiary/Exploratory: 
Tertiary/Exploratory: 
To compare the concentrations of etrasimod in PK 
samples collected using micro sampling device 
against those using venous blood sampling. 
Plasma concentrations of etrasimod obtained 
via micro sampling compared to venous 
sampling at pre-dose and at 2 and 4 hrs post-
dose.
4. STUDY DESIGN
4.1. Overall Design
This is a Phase 1, open-label, single-dose, fixed-sequence, crossover sub study in a single 
cohort of approximately 8 healthy male or female participants conducted using a hybrid DCT
design. 
The study will consist of 2 treatments. Participants will receive the two Treatments F and G 
in a fixed sequence as shown below.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 32
Fixed Treatment 
Sequence (n=8)
Period 1
Period 2
F
G
Treatment F: Single oral dose of etrasimod 2 mg, DCT with practice sessions* (Reference)
Treatment G: Single oral dose of etrasimod 2 mg, DCT without practice sessions** (Test)
* Practice of Tasso and Wearable Monitoring Devices on Day 2 at CRU; participant self-assessment remotely for vitals 
and ECG (Days 3-5) and PK samples (Days 3-8) 
** Participant self-assessment using Tasso and Wearable Monitoring Devices on Days 1-2 at CRU; and remotely on 
Days 3-8 
Following are the key elements of the design of this hybrid decentralized clinical trial. 
Participants will be discharged from the CRU on Day 2 of each Period, following practice 
sessions (Period 1 only) with the use of Tasso for serum PK sampling and wearable devices 
for safety monitoring, and the completion of all assessments that are planned to be performed 
at the CRU. The Tasso OnePlus, high-volume liquid blood collection device, will be used for 
micro-PK sampling and the blood samples collected by participants will be sent to the CRU 
within 72 hours of collection for processing of serum. The BioBeat Patch and PCA500 
wearable monitoring devices will be used for collection of vitals and ECGs, respectively, in 
Periods 1 and 2.  Each treatment period is 8 days that includes dosing, PK sampling, safety 
assessments, and practice (Period 1 only) with use of wearable devices and Tasso sampling. 
The PK and safety (ECGs and vitals) assessments through Day 2 of Period 1 will be 
performed by the CRU staff. Following practice with the Tasso and wearable monitoring 
devices on Day 2 of Period 1, the assessments on Days 3 to 8 (remote) of Period 1 and on 
Days -1 to 2 (at CRU) and 3 to 8 (remote) of Period 2 will be self-performed by the 
participants. Participants will be discharged from the CRU on Day 2 Periods 1 and 2. 
Participants will receive an emergency card for contacting the CRU and will be provided 
detailed instructions to call PCRU for reporting of an AE. Additionally, the participants will 
be provided with diaries to record information about PK sampling times, concomitant 
medication(s) and AEs during the self-assessment phase following discharge on Day 2 of 
Periods 1 and 2. The participants will be provided instructions for returning the wearable 
devices and other study related materials study following completion of all assessments on 
Day 8 of Period 2. The total planned duration of participation from the screening visit to the 
last follow-up phone call, is approximately 9 weeks.
Since etrasimod has a half-life approximately 30 hours, there will be an 8-day washout
between each dose.
In both Periods 1 and 2, capillary blood samples (using micro sampling Tasso device) for PK 
analysis will be collected at predose and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168 
hours postdose (SoA). Venous blood samples for PK analysis will be collected predose and 
at 2 and 4 hours postdose (SoA). Micro PK sampling occurs after venous PK blood sampling; 
samples will be taken from the alternate arms from one sampling time to the next.
Participants will be screened within 28 days of the first dose of study intervention and if all 
entry criteria are fulfilled, the participants will report to the CRU on the day prior to Day 1 
dosing (Day -1). On Day 1 of each period, participants will receive a single dose of study 
intervention at the CRU. Administration of etrasimod will be oral via dosing of clinical IR 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 33
tablet 2 mg with water as per dosing instructions. Participants will be fasted for at least 10 
hours predosing and 4 hours postdosing.
Participants will be confined in the CRU for a total of at least 2 days and discharged on Day 
2 of each Period. A follow-up phone call will be made at least 28 calendar days and up to 35 
calendar days after the last administration of the study intervention to capture any potential 
AEs and confirm appropriate contraceptive usage.
Tolerability and safety will be assessed for all treatments by monitoring AEs. Participants 
who withdraw from the study or whose PK samples are determined to be non-analyzable may 
be replaced at the discretion of the of the investigator upon consultation with the sponsor.
4.2. Scientific Rationale for Study Design
The purpose of the sub study is to determine the PK and to assess the safety and tolerability 
of etrasimod clinical IR tablets 2 mg under fasted conditions in healthy adult participants in a 
hybrid DCT design. Since etrasimod has a long half-life of approximately 30 hours, requiring 
blood sampling up to 168 hours post-dose for PK characterization of its PK profile, standard 
crossover BA study designs can require relatively long CRU stay requirements and may 
impede participant recruitment and retention. Therefore, this hybrid DCT design sub study is 
designed to investigate the utility of self-assessment of PK, vitals and ECGs remotely by 
study participants in two fixed-sequence crossover study Periods, wherein Period 1 will 
include assessments by CRU staff up to Day 2 and a training session for participants. The 
participants will perform self-assessments on Days 3 to 8 (remote) of Period 1 and on Days -
1 to 2 (at CRU) and 3 to 8 (remote) of Period 2. On Day 1 of each period, participants will 
receive a single dose of etrasimod IR tablet 2 mg at the CRU. 
4.2.1. Rationale for ECG Measurements
In the heart, S1P1 is expressed on atrial myocytes and is associated with the regulation of 
heart rate. S1P1 agonism activates both G alpha i (Gi) and β-arrestin signaling pathways. 
β-arrestin activation leads to receptor internalization, while Gi coupled signaling activates 
GIRK channels that regulate potassium efflux and membrane potential. As a result, there is a 
transient, first dose associated, chronotropic (slowing of HR) and dromotropic (slowing of 
AV nodal conduction) effects associated with etrasimod (a class effect). For all Phase 1 
studies, intensive ECG have been taken for the first 6-hours post first dose. For this study, 
this practice should be in place until the NDA is approved.
4.2.2. Rationale for PR and BP Monitoring
In addition to the transient, first dose associated, chronotropic effect associated with 
etrasimod, hypertension has been observed with S1P receptor modulators and AEs of 
hypertension have been reported. For all phase 1 studies, intensive BP and PR monitoring 
post dose has been undertaken and this will continue for this study.
4.2.3. Choice of Contraception/Barrier Requirements
Etrasimod is known to cause risk for severe manifestations of developmental toxicity in 
humans or suspected on the basis of the intended pharmacology. Therefore, the use of a 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 34
highly effective method of contraception is required for both female and male participants 
(see Appendix 4).
4.3. Justification for Dose
The dose of etrasimod 2 mg once daily has been shown to be efficacious and safe in 
moderate to severely active adult UC patients.  
This study is designed to evaluate PK of etrasimod 2 mg clinical IR tablet formulation in 
healthy adult participants. 
4.4. End of Study Definition
The end of the study is defined as the date of the last visit of the last participant in the study 
or last scheduled procedure shown in the SoA and the investigator has reviewed the final 
safety data and determined that no additional evaluation is required.
A participant is considered to have completed the study if they have completed all periods of 
the study, including the last visit or the last scheduled procedure shown in the SoA.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled, including 
participants across diverse and representative racial and ethnic backgrounds. If a 
prescreening tool is utilized for study recruitment purposes, it will include collection of 
information that reflects the enrollment of a diverse participant population including, where 
permitted under local regulations, age, sex, race, and ethnicity. The following eligibility 
criteria are designed to select participants for whom participation in the study is considered 
appropriate. All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Age and Sex:
1. Male and female participants aged 18 years or older (or the minimum age of consent 
in accordance with local regulations) at screening who are overtly healthy as 
determined by medical evaluation including a detailed medical history, full
physical exam, which includes BP and pulse rate measurement, clinical laboratory 
tests, temperature, and 12-lead ECG.

Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and 
female (Section 10.4.2) participants.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 35
Other Inclusion Criteria:
2. BMI of 16 to 32 kg/m2; and a total body weight > 50 kg (110 lb).
3. Participants who are willing and able to comply with all scheduled visits, treatment 
plan, laboratory tests, lifestyle considerations, and other study procedures.
4. Capable of giving signed informed consent as described in Appendix 1, which 
includes compliance with the requirements and restrictions listed in the ICD and in 
this protocol.
5. Capable of using wearable monitoring devices for the duration of this study, 
according to the requirements specified in the SoA.
5.2. Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
1. Evidence or history of clinically significant hematological, renal, endocrine, 
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, 
anaphylactic, ophthalmologic disorders (such as macular edema, uveitis, retinopathy), 
or allergic disease (including drug allergies, but excluding untreated, asymptomatic, 
seasonal allergies at the time of dosing).

Myocardial infarction, unstable angina, stroke/transient ischemic attack, 
decompensated heart failure requiring hospitalization, or Class III/IV heart 
failure ≤6 months prior to study intervention

Second- or third-degree AV block, sick sinus syndrome without a functional 
pacemaker, or periods of asystole for 3 seconds without an implanted cardiac 
defibrillator

Recurrent symptomatic bradycardia or recurrent cardiogenic syncope

History of congenital long QT syndrome

Other medical or psychiatric condition including recent (within the past year) 
or active suicidal ideation/behavior, laboratory abnormality or other conditions 
that may increase the risk of study participation or, in the investigator’s 
judgment, make the participant inappropriate for the study
2. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
3. Known immunodeficiency disorder, including positive serology for HIV, or a first 
degree relative with a hereditary immunodeficiency.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 36
4. Infection with hepatitis B or hepatitis C viruses according to protocol specific testing 
algorithm history.

For hepatitis B, all participants will undergo testing for HbsAg and HbcAb.

If HbsAg is positive, the participant must be excluded from participation in the 
study.

If HbsAg and HbcAb are both negative, the participant is eligible for study 
inclusion.

If HbsAg is negative and HbcAb is positive, HbsAb should be evaluated:

If HbsAb is negative, the participant must be excluded from participation in 
the study;

If HbsAb is positive, the participant is eligible for study inclusion.

For hepatitis C, all participants will undergo testing for HCVAb. Only 
participants who are HCVAb negative are eligible.
5. Participants with any of the following acute or chronic infections or infection history:

Any infection requiring treatment within 2 weeks prior to dosing.

Any infection requiring hospitalization or parenteral antimicrobial therapy 
within 60 days of the first dose of study intervention.

Any infection judged to be an opportunistic infection or clinically significant 
by the investigator, within the past 6 months of the first dose of study 
intervention.

Known active or history of recurrent bacterial, viral, fungal, mycobacterial or 
other infections.

History of recurrent (more than one episode of) localized dermatomal herpes 
zoster, or history of disseminated (single episode) herpes simplex or 
disseminated herpes zoster.

History of febrile illness within 5 days prior to the first dose of study 
intervention.
6. History of any lymphoproliferative disorder such as EBV related lymphoproliferative 
disorder, history of lymphoma, history of leukemia, or signs or symptoms suggestive 
of current lymphatic or lymphoid disease. Known present or a history of malignancy 
other than a successfully treated or excised nonmetastatic basal cell or squamous cell 
cancer of the skin or cervical carcinoma in situ.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 37
7. Evidence of untreated or inadequately treated active or latent Mycobacterium TB 
infection as evidenced by the following:

A positive QFT-G test performed within the 12 weeks prior to screening. If the 
laboratory reports the test as indeterminate, the test should be repeated. If the 
result of the repeat test is indeterminate, a PPD test may be substituted for the 
QFT-G test only with approval from the Pfizer Medical Monitor on a case-by-
case basis.

History of either untreated or inadequately treated latent or active TB infection.

If a participant has previously received an adequate course of therapy for either 
latent (9 months of isoniazid in a locale where rates of primary multi-drug 
resistant TB infection are <5% or an acceptable alternative regimen) or active 
(acceptable multi-drug regimen) TB infection, neither a QFT-G test nor a PPD 
test need be obtained. Details of the previous course of therapy (eg,
medication(s) used, dose, duration of therapy) should be documented in the 
source documentation.

A participant who is currently being treated for active or latent TB infection 
must be excluded from the study.
8. Participants with ANY of the following abnormalities in clinical laboratory tests at 
screening or Day -1, as assessed by the study-specific laboratory and confirmed by a 
single repeat test, if deemed necessary: 

WBC <3500/mm3 (<3.5 × 109 cells/L)

ANC <1500/mm3 (<1.5 × 109 cells/L)

ALC <800/mm3 (<0.8 × 109 cells/L)

Platelet count <100/mm3 (<100 × 109 cells/L)

Hemoglobin <10 g/dL

AST or ALT level > ULN;

Total bilirubin level > ULN; participants with a history of Gilbert’s syndrome 
may have direct bilirubin measured and would be eligible for this study 
provided the direct bilirubin level is ≤ULN;

Renal impairment as defined by an eGFR (units of mL/min/1.73m²) of <60 
mL/min(/1.73m²). Based upon participant age at screening, eGFR will be 
calculated using the recommended CKD-EPI equation in Section 10.6.2 to 
determine eligibility (Screat-based formula)

In the opinion of the investigator or Pfizer (or designee), have any clinically 
significant laboratory abnormality that could affect interpretation of study data 
or the participant’s participation in the study.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 38
Prior/Concomitant Therapy:
9. Use of prescription or nonprescription drugs and dietary and herbal supplements 
within 5 half-lives plus 14 days prior to the first dose of study intervention. (Refer to 
Section 6.9 Prior and Concomitant Therapy for additional details).
Prior/Concurrent Clinical Study Experience:
10. Previous administration with an investigational product (drug or live or attenuated
vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives 
preceding the first dose of study intervention used in this study (whichever is longer). 
Diagnostic Assessments:
11. A positive urine drug test.
12. A positive pregnancy test.
13. Screening or Day 1 prerandomization vital signs (taken in the supine position) with a 
HR <50 bpm OR systolic BP <90 mm Hg or ≥140 mm Hg OR diastolic BP 
<50 mm Hg or ≥90 mm Hg. Abnormal vital signs should be confirmed by 2 repeat 
measurements. Abnormal results that are confirmed on a repeat assessment are 
considered exclusionary.
14. Standard 12-lead ECG that demonstrates clinically relevant abnormalities that may 
affect participant safety or interpretation of study results (eg, QTcF >450 ms, 
complete LBBB, signs of an acute or indeterminate- age myocardial infarction, ST-T 
interval changes suggestive of myocardial ischemia, second- or third- degree AV 
block, or serious bradyarrhythmias or tachyarrhythmias). If QTcF exceeds 450 ms, or 
QRS exceeds 120 ms, the ECG should be repeated twice and the average of the 
3 QTcF or QRS values used to determine the participant’s eligibility. 
Computer-interpreted ECGs should be overread by a physician experienced in 
reading ECGs before excluding a participant.
Other Exclusion Criteria:
15. History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 
5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 
1 ounce (30 mL) of 40% spirit, or 3 ounces (90 mL) of wine).
16. Use of tobacco/nicotine containing products in excess of 5 cigarettes/day.
17. WOCBP who are unwilling or unable to use an acceptable method of contraception as 
outlined in Section 10.4 during the intervention period and for at least 28 days after 
the last dose of study intervention.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 39
18. History of severe allergic or anaphylactic reactions.
19. Unwilling or unable to comply with the criteria in the Lifestyle Considerations
section of this protocol.
20. Investigator site staff directly involved in the conduct of the study and their family 
members, site staff otherwise supervised by the investigator, and sponsor and sponsor 
delegate employees directly involved in the conduct of the study and their family 
members.
5.3. Lifestyle Considerations
The following guidelines are provided:
5.3.1. Contraception
The investigator or their designee, in consultation with the participant, will confirm that the 
participant is utilizing an appropriate method of contraception for the individual participant 
and their partner(s) from the permitted list of contraception methods (see Appendix 4,
Section 10.4.4) and will confirm that the participant has been instructed in its consistent and 
correct use. The investigator or designee will advise the participant to seek advice about the 
donation and cryopreservation of germ cells prior to the start of study intervention, if 
applicable.
At time points indicated in SoA, the investigator or designee will inform the participant of 
the need to use highly effective contraception consistently and correctly and document the 
conversation and the participant’s affirmation in the participant’s chart. Participants need to 
affirm their consistent and correct use of at least 1 of the selected methods of contraception, 
considering that their risk for pregnancy may have changed since the last visit. 
In addition, the investigator or designee will instruct the participant to call immediately if the 
selected contraception method is discontinued and document the requirement to use an 
alternate protocol-specified method, including if the participant will no longer use abstinence 
as the selected contraception method, or if pregnancy is known or suspected in the participant 
or partner.
5.3.2. Meals and Dietary Restrictions

Participants must abstain from all food and drink (except water) at least 4 hours prior 
to any safety laboratory evaluations and 10 hours prior to the collection of the predose 
PK sample.

Water is permitted until 1 hour prior to study intervention administration. Water may 
be consumed without restriction beginning 1 hour after dosing. Noncaffeinated drinks 
(except grapefruit or grapefruit-related citrus fruit juices—see below) may be 
consumed with meals and the evening snack.

Lunch will be provided approximately 4 hours after dosing.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 40

Dinner will be provided approximately 9 to 10 hours after dosing.

An evening snack may be permitted.

Participants will refrain from consuming red wine, grapefruit, or grapefruit-related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from 7 days prior to the first 
dose of study intervention until collection of the final PK blood sample.  

While participants are confined, their total daily nutritional composition should be 
approximately 55% carbohydrate, 30% fat, and 15% protein. The daily caloric intake 
per participant should not exceed approximately 3200 kcal.
5.3.3. Caffeine, Alcohol, and Tobacco
Participants will abstain from caffeine-containing products for 24 hours prior to the start of 
dosing until collection of the final PK sample of each study period. 

Participants will abstain from alcohol for 24 hours prior (or as specified above for red 
wine) to admission to the CRU and continue abstaining from alcohol until collection 
of the final PK sample of each study period. Participants may undergo an alcohol 
breath test or blood alcohol test at the discretion of the investigator.

Participants will abstain from the use of tobacco- or nicotine-containing products for 
24 hours prior to dosing and during confinement in the CRU.
5.3.4. Activity

Participants will abstain from strenuous exercise (eg, heavy lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory tests. Walking at a normal pace will be permitted;

In order to standardize the conditions on PK sampling days, participants will be 
required to refrain from lying down (except ECG measurements), eating, and 
drinking beverages other than water during the first 4 hours after dosing.
5.3.5. Vaccination(s)
Vaccination with live attenuated replication-competent vaccines is prohibited within the 
4 weeks prior the first dose of study intervention, while receiving study intervention, and for 
4 weeks after the last dose of study intervention. Similarly, current routine household contact 
with individuals who have been vaccinated with live attenuated, replication-competent 
vaccines should be avoided while receiving study intervention and for 4 weeks after the last 
dose of study intervention. Following vaccination with a live attenuated 
replication-competent vaccine, the virus may be shed in bodily fluids, including stool, and 
there is a potential risk that the virus may be transmitted.
Such vaccines include, but are not limited to: Flu Mist® (intranasal influenza vaccine), 
attenuated rotavirus vaccine, varicella (chickenpox) vaccine, attenuated typhoid fever 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 41
vaccine, oral polio vaccine, MMR vaccine, vaccinia (smallpox) vaccine, and Zostavax® 
(zoster vaccine live). 
Live attenuated vaccines that are known not to be replication-competent in humans are 
permitted. Such vaccines include but are not limited to the Modified Vaccinia Ankara 
Bavarian Nordic (Jynneos®, Imvamune®, Imvanex®) smallpox and monkeypox vaccine. By 
contrast, the ACAM2000 smallpox and monkeypox vaccine is prohibited because it is live 
and replicates in humans.
Vaccines (including COVID-19 vaccines) that are not live attenuated are permitted.
Individuals receiving immunosuppressive therapy may have a diminished response to 
vaccination.
5.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently enrolled in the study. Screen failure data are collected and remain as 
source and are not reported on the CRF.
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened. 
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY
Study interventions are all prespecified investigational and noninvestigational medicinal 
products, medical devices, and other interventions (eg, surgical and behavioral) intended to 
be administered to the study participants during the study conduct.
For the purposes of this protocol, study intervention refers to etrasimod.
6.1. Study Intervention(s) Administered
Study interventions will be administered orally and according to the conditions described in 
the SoA and Meals and Dietary Restrictions of this protocol.
Participants will receive a single dose of etrasimod on Day 1 of each period at the CRU.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 42
Study Intervention(s)
Intervention Name
Etrasimod clinical IR tablets, 2 mg
Reference product
Type
drug
Use
Experimental
IMP or NIMP/AxMP
IMP
Dose Formulation
Coated tablets containing 2 mg etrasimod each
Unit Dose Strength(s)
2 mg/tablet
Dosage Level(s)
2 mg per Period
Route of 
Administration
Oral
Sourcing
Etrasimod provided centrally by the sponsor.
See IPM for more information.
Packaging and 
Labeling
Study intervention will be provided in HDPE bottle.
Each bottle will be labeled as required per country requirement.
SRSD
IB
Current/Former 
Name(s) or Alias(es)
Etrasimod/PF-07915503, APD334
Study Arm(s)
Arm Title
Period 1
Period 2
Arm Description
Participants will receive a single dose of etrasimod 2 mg on Day 1 of each 
period. Participants will be assigned to a fixed crossover sequence to receive 
single-dose Treatments F and G in Periods 1 and 2, respectively. 
In each period, etrasimod 2 mg clinical IR tablet will be administered with 
240 mL water under fasting conditions.
Etrasimod will be supplied as clinical IR tablet to the CRU in bulk in HDPE bottles. 
6.1.1. Administration
On Day 1 of each period, following an overnight fast of at least 10 hours, participants will 
receive study intervention at approximately 0800 hours (plus or minus 2 hours). Investigator 
site personnel will administer study intervention during each period.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 43
Etrasimod clinical IR tablets will be administered with ambient temperature water to a total 
volume of approximately 240 mL. Participants will swallow the clinical IR tablets whole and 
will not manipulate or chew the study intervention prior to swallowing.
In order to standardize the conditions on PK sampling days, all participants will be required 
to refrain from lying down (except when required for ECG measurements), eating, and 
drinking beverages other than water during the first 4 hours after dosing.
Administration of study intervention(s) will be performed by an appropriately qualified and 
trained member of the study staff as allowed by local, state, and institutional guidance. 
Following administration of study intervention(s), participants will be observed for the
complete period/study by an appropriately qualified and trained member of the study staff. 
Appropriate medication and other supportive measures for management of a medical 
emergency will be available in accordance with local guidelines and institutional guidelines.
6.1.2. Medical Devices 
1. Medical devices (not manufactured by or for Pfizer) provided for use in this study are 
Tasso OnePlus, BioBeat and PCA500.
2. Instructions for medical device use are provided in the IPM.
3. All medical device deficiencies (including malfunction, use error, and inadequate 
labeling) for the above-listed medical devices shall be documented and reported by the 
investigator throughout the clinical investigation (see Section 8.4.9) and appropriately 
managed by the sponsor.
6.2. Preparation, Handling, Storage, and Accountability
1.
The investigator or designee must confirm that appropriate conditions (eg, temperature) 
have been maintained during transit for all study interventions received and any 
discrepancies are reported and resolved before use of the study intervention. 
2.
Only participants enrolled in the study may receive study intervention and only 
authorized site staff may supply, prepare, and/or administer study intervention.
3.
All study interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking days must 
indicate the minimum and maximum temperatures since previously documented upon 
return to business.
4.
Any excursions from the study intervention label storage conditions should be reported 
to Pfizer upon discovery along with actions taken. The site should actively pursue 
options for returning the study intervention to the labeled storage conditions, as soon as 
possible. Once an excursion is identified, the study intervention must be quarantined 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 44
and not used until Pfizer provides permission to use the study intervention. Specific 
details regarding the excursion definition and information to report for each excursion 
will be provided to the site in the IPM.
5.
Any storage conditions stated in the SRSD will be superseded by the storage conditions 
stated on the label.
6.
Study interventions should be stored in their original containers and in accordance with 
the labels. 
7.
The investigator, institution, head of the medical institution (where applicable), or 
authorized site staff is responsible for study intervention accountability, reconciliation, 
and record maintenance (ie, receipt, reconciliation, and final disposition records), such 
as the IPAL or sponsor-approved equivalent. All study interventions will be accounted 
for using a study intervention accountability form/record.
8.
Further guidance and information for the final disposition of unused study interventions 
are provided in the PCRU’s local/site procedures. All destruction must be adequately 
documented. If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroyed in compliance with applicable 
environmental regulations, institutional policy, and any special instructions provided by 
Pfizer.
9.
Upon identification of a product complaint, notify the sponsor within 1 business day of 
discovery as described in the IPM.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study intervention ready for administration or dispensing to the participant by qualified 
staff. Dispensing is defined as the provision of study intervention, concomitant treatments, 
and accompanying information by qualified staff member(s) to a healthcare provider, 
participant, in accordance with this protocol. Local health authority regulations or 
investigator site guidelines may use alternative terms for these activities.
Etrasimod clinical IR tablets will be dispensed at the CRU in the individual dosing containers 
by 2 operators, 1 of whom is an appropriately qualified pharmacist. Prepared doses will be 
provided in unit dose containers and labeled in accordance with Pfizer regulations and the 
clinical site’s labeling requirements. 
Dispensing will be performed in CRU by an appropriately qualified and experienced member 
of the study staff (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacy 
assistant/technician, or pharmacist) as allowed by local, state, and institutional guidance.
Only qualified personnel who are familiar with procedures that minimize undue exposure to 
themselves and to the environment should undertake the preparation, handling, and safe 
disposal of study interventions.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 45
6.3. Assignment to Study Intervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participants are enrolled.
The investigator will assign participant numbers to the participants as they are screened for 
the study. Pfizer will provide a randomization schedule to the investigator and, in accordance 
with the randomization numbers, the participant will receive the study treatment regimen 
assigned to the corresponding randomization number.
6.4. Blinding
This is an open-label study. 
6.5. Study Intervention Compliance
When the individual dose for a participant is prepared from a bulk supply, the preparation of 
the dose will be confirmed by a second qualified member of the study site staff.
When participants are dosed, they will receive study intervention directly from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered will be recorded in the source documents and recorded in the CRF. The dose of 
study intervention and study participant identification will be confirmed at the time of dosing 
by a member of the study site staff. Study site personnel will examine each participant’s 
mouth to ensure that the study intervention was ingested.
A record of the number of clinical IR tablets and mini tablets dispensed to and taken by each 
participant must be maintained and reconciled with study intervention and compliance 
records. Intervention start and stop dates, including dates for intervention delays, will also be 
recorded in the CRF.
6.6. Dose Modification
Not applicable.
6.7. Continued Access to Study Intervention After the End of the Study
No study intervention will be provided to participants at the end of their study participation.
6.8. Treatment of Overdose
For this study, any dose of etrasimod greater than 2 mg within a 24-hour time period will be 
considered an overdose.
There is no specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.
Contact the study medical monitor within 24 hours.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 46
2.
Closely monitor the participant for any AEs/SAEs and laboratory abnormalities as 
medically appropriate and follow-up until resolution, stabilization, the event is 
otherwise explained, or the participant is lost to follow-up (as defined in 
Section 7.3).
3.
Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF.
4.
Overdose is reportable to Pfizer Safety only when associated with an SAE.
5.
Obtain a blood sample for PK analysis within 7 days from the date of the last dose 
of study intervention if requested by the study medical monitor (determined on a 
case-by-case basis).
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the study medical monitor as needed based on the clinical evaluation of the 
participant.
6.9. Prior and Concomitant Therapy
Use of prescription or nonprescription drugs and dietary and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study 
intervention. Limited use of nonprescription medications that are not believed to affect 
participant safety or the overall results of the study may be permitted on a case-by-case basis 
following approval by the sponsor. Acetaminophen/paracetamol may be used at doses of 
≤2 g/day.
Hormonal contraceptives that meet the requirements of this study are allowed to be used in 
participants who are WOCBP (see Appendix 4). Postmenopausal hormonal therapy is 
allowed.
All concomitant treatments taken during the study must be recorded with indication, daily 
dose, and start and stop dates of administration. All participants will be questioned about 
concomitant treatment at each clinic visit.
Treatments taken within 28 days before the first dose of study intervention will be 
documented as a prior treatment. Treatments taken after the first dose of study intervention 
will be documented as concomitant treatments.
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study Intervention
It may be necessary for a participant to permanently discontinue study intervention. Reasons 
for permanent discontinuation of study intervention include the following:

Adverse event


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 47

Pregnancy

Withdrawal by participant
Discontinuation of study intervention does not represent withdrawal from the study. If study 
intervention is permanently discontinued, the participant should remain in the study to be 
evaluated for safety. See the SoA for data to be collected at the time of discontinuation of 
study intervention and follow-up for any further evaluations that need to be completed.
In the event of discontinuation of study intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of study intervention or also from study procedures, posttreatment study follow-up, 
and/or future collection of additional information.
7.1.1. Liver Injury 
A participant who meets the criteria as described in Appendix 5 will be withdrawn from 
study intervention. 
7.1.2. ECG Changes
Participants must permanently discontinue study intervention if suspected intolerance
associated with first dose cardiac effects (Section 2.3.1).
If an ECG shows a new onset QTc interval above 500 ms during the treatment period, a 
repeat ECG is warranted. If this abnormal finding is confirmed, study intervention must be 
interrupted. Effective diagnostic and therapeutic strategies should be employed.
Reversible causes of prolonged QTc interval (eg, electrolyte abnormalities or 
hypomagnesemia), should be corrected as clinically indicated. When evaluating a participant 
with new onset QTc interval above 500 ms, referral to a cardiologist experienced in treating 
cardiac conduction disorders should be considered. Re-initiation of study treatment can only 
be considered after all of the following have occurred: 

The QTcF interval is <450 ms (males) or <470 ms (females), 

The QTc prolongation is considered by the investigator and confirmed by the 
cardiologist as not related to study treatment and likely caused by other factors, 

Individual risk-benefit is favorable (as determined by the investigator, in agreement 
with the cardiologist), and 

After discussion with the Medical Monitor.
If a clinically significant finding is identified (including, but not limited to, changes from 
baseline in QTcF after enrollment), the investigator or qualified designee will determine if 
the participant can continue in the study and if any change in participant management is 
needed. This review of the ECG printed at the time of collection or acquired using wearable 
monitoring device must be documented. Any new clinically relevant finding should be 
reported as an AE.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 48
7.1.3. Pregnancy
Pregnancy tests are conducted as per SoA and dosing of study intervention will occur only in 
the presence of a negative pregnancy test. If a participant is confirmed to be pregnant (See 
Section 8.3.6) during study, further dosing with study intervention will be discontinued 
immediately and permanently. 
7.1.4. COVID-19
If a participant has COVID-19 during the study, this should be reported as an AE or SAE (as 
appropriate) and appropriate medical intervention provided. Temporary discontinuation of 
the study intervention may be medically appropriate until the participant has recovered from 
COVID-19. 
It is recommended that the investigator discuss temporary or permanent discontinuation of 
study intervention with the study medical monitor. 
7.2. Participant Discontinuation/Withdrawal From the Study
A participant may withdraw from the study at any time at their own request. Reasons for 
discontinuation from the study include the following:

Refused further follow-up

Lost to follow-up

Death

Study terminated by sponsor

Adverse event
At the time of discontinuing from the study, if possible, an early discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study 
discontinuation and follow-up and for any further evaluations that need to be completed. 
The early discontinuation visit applies only to participants who are enrolled/randomized and 
then are prematurely withdrawn from the study. Participants should be questioned regarding 
their reason for withdrawal.
The participant will be permanently discontinued from the study intervention and the study at 
that time.
If a participant withdraws from the study, they may request destruction of any remaining 
samples taken and not tested, and the investigator must document any such requests in the 
site study records and notify the sponsor accordingly.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 49
If the participant withdraws from the study and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations will be performed and no 
additional data will be collected. The sponsor may retain and continue to use any data 
collected before such withdrawal of consent.
7.2.1. Withdrawal of Consent 
Participants who request to discontinue receipt of study intervention will remain in the study 
and must continue to be followed for protocol-specified follow-up procedures. The only 
exception to this is when a participant specifically withdraws consent for any further contact 
with them or persons previously authorized by the participant to provide this information. 
Participants should notify the investigator in writing of the decision to withdraw consent 
from future follow-up, whenever possible. The withdrawal of consent should be explained in 
detail in the medical records by the investigator, as to whether the withdrawal is only from 
further receipt of study intervention or also from study procedures and/or posttreatment study 
follow-up, and entered on the appropriate CRF page. In the event that vital status (whether 
the participant is alive or dead) is being measured, publicly available information should be 
used to determine vital status only as appropriately directed in accordance with local law.
7.3. Lost to Follow-Up
A participant will be considered lost to follow-up if the participant repeatedly fails to return 
for scheduled visits and is unable to be contacted by the study site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:

The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible. Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should 
continue in the study;

Before a participant is deemed lost to follow-up, the investigator or designee must 
make every effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record;

Should the participant continue to be unreachable, the participant will be considered 
to have withdrawn from the study. 
8. STUDY ASSESSMENTS AND PROCEDURES
8.1. Administrative and Baseline Procedures
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any study-specific procedures. 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 50
Study procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study intervention 
to confirm that they meet the study population criteria for the study. If the time between 
screening and dosing exceeds 28 days as a result of unexpected delays (eg, delayed drug 
shipment), then participants do not require rescreening if the laboratory results obtained prior 
to first dose administration meet eligibility criteria.
A participant who qualified for this protocol but did not enroll from an earlier cohort/group 
may be used in a subsequent cohort/group without rescreening, provided laboratory results 
obtained prior to the first dose administration meet eligibility criteria for this study. In 
addition, other clinical assessments or specimen collections, eg, retained research samples, 
may not need to be repeated, as appropriate.
Every effort should be made to ensure that protocol-required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may be 
circumstances outside the control of the investigator that make it unfeasible to perform the 
test. In these cases, the investigator must take all steps necessary to ensure the safety and 
well-being of the participant. When a protocol-required test cannot be performed, the 
investigator will document the reason for the missed test and any corrective and preventive 
actions that they have taken to ensure that required processes are adhered to as soon as 
possible. The study team must be informed of these incidents in a timely manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study.
The total blood sampling volume for individual participants in this study is approximately 
100 mL. The actual collection times of blood sampling may change. Additional blood 
samples may be taken for safety assessments at times specified by Pfizer, provided the total 
volume taken during the study does not exceed 550 mL during any period of 56 consecutive 
days.
To prepare for study participation, participants will be instructed on the information in the 
Lifestyle Considerations and Prior and Concomitant Therapy sections of the protocol.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 51
8.1.1. Baseline Procedures
All procedures listed in the SoA must be conducted at this visit.
SoA must be conducted at the screening visit.
8.2. Efficacy Assessments
Efficacy parameters are not evaluated in this study.
8.3. Safety Assessments
Planned time points for all safety assessments are provided in the SoA. Unscheduled safety 
measurements may be obtained at any time during the study to assess any perceived safety 
issues.
8.3.1. Physical Examinations
A complete physical examination will include, at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and 
neurological systems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respiratory and cardiovascular systems, and participant reported symptoms.
Complete physical examination must either be conducted at screening or upon admission on 
Day -1 only; targeted physical examination may be performed as appropriate at the 
investigator’s discretion if there are findings during the previous examination, new/open 
adverse events.
Physical examinations may be conducted by a physician, trained physician’s assistant, or 
nurse practitioner as acceptable according to local regulation. 
Ophthalmologic examination, including fundoscopy, will be conducted by an 
ophthalmologist at baseline (Screening) and for clinical monitoring of any signs or symptoms
throughout the trial, as needed.
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. Participants must remove shoes, bulky layers of clothing, and jackets so that only 
light clothing remains. They must also remove the contents of their pockets and remain still 
during measurement of weight. 
Physical examination findings collected during the study will be considered source record
and will not be required to be reported, unless otherwise noted. Any untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE (Appendix 3) must be reported according to the processes in 
Sections 8.4.1 to 8.4.3.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 52
8.3.2. Vital Signs
Vital signs (BP, PR and temperature) will be collected at times specified in the protocol SoA.
8.3.2.1. Blood Pressure and Pulse Rate
At screening, vital signs will be measured using standard methodology. Supine BP will be 
measured with the participant’s arm supported at the level of the heart, and recorded to the 
nearest mm Hg after approximately 5 minutes of rest. The same arm (preferably the 
dominant arm) will be used throughout the study. Participants should be instructed not to 
speak during measurements. The use of an automated device for measuring BP and pulse rate
is acceptable; however, when done manually, pulse rate will be measured in the 
brachial/radial artery for at least 30 seconds. 
During periods 1 and 2, ambulatory BP and PR will be monitored using the BioBeat chest-
monitor, a single-participant-use device and web-enabled management platform either (1) at 
the CRU by the CRU staff and/or by study participants or (2) remotely by the study 
participants, as specified in the protocol SoA. Investigational site staff and study participants 
will be provided training as well as the BioBeat user manual.
When the timing of these measurements coincides with a blood collection, BP and pulse rate
should be obtained prior to the nominal time of the blood collection. Additional collection 
times, or changes to collection times, of BP and pulse rate will be permitted, as necessary, to 
ensure appropriate collection of safety data.
Any untoward vital sign findings that are identified during the active collection period and 
meet the definition of an AE or SAE (Appendix 3) must be reported according to the 
processes in Sections 8.4.1 to 8.4.3.
8.3.2.2. Temperature 
Temperature will be measured orally. No eating, drinking, or smoking is allowed for 
15 minutes prior to the measurement.
8.3.3. Electrocardiograms
Electrocardiograms (except at screening) will be obtained using the PCA 500 which is a 
wearable ECG monitor. The PCA500 provides 12-lead ECG monitoring and recording which 
is transmitted periodically at pre-specified time intervals. Investigational site and study 
participant training are supplemented by availability of the PCA500 user manual. 
At screening, standard 12-lead ECGs will be collected to assess and quantify HR, PR, QT, 
QTcF, and QRS intervals. During Periods 1 and 2, ECGs will be collected using the PCA500 
wearable monitoring device, at the times specified in the protocol SoA, either (1) at the CRU 
by the CRU staff or by the study participant or (2) remotely by the study participant.
All scheduled ECGs should be performed after the participant has rested quietly in a supine 
position or in the most recumbent position possible for at least 5 minutes.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 53
The pre-etrasimod dose 12-lead ECGs will be done in triplicate. Triplicate 12-lead ECGs will 
be obtained approximately 5 minutes apart; the average of the triplicate ECG measurements 
collected pre-etrasimod dose on Day 1 of each period will serve as each participant’s baseline 
QTcF value. 
To ensure safety of the participants, a qualified individual at the investigator site will make 
comparisons to baseline measurements from the current period. Additional ECG monitoring 
will occur if a) the mean value from the triplicate measurements for any postdose QTcF
interval remains ≥60 ms from the baseline and is >450 ms; or b) an absolute QTcF value is 
≥500 ms for any scheduled ECG for greater than four hours (or sooner, at the discretion of 
the investigator); or c) QTcF values get progressively longer. If any of these conditions 
occurs, then a single ECG measurement must be repeated at least hourly until QTcF values 
from 2 successive ECGs fall below the threshold value that triggered the repeat 
measurement.
In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads be placed in the 
same positions each time in order to achieve precise ECG recordings. If a machine-read QTc 
value is prolonged, as defined above, repeat measurements may not be necessary if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range. Please refer to Section 7.1.2 for guidance on QTcF changes management.
ECG values of potential clinical concern are listed in Appendix 7.
8.3.4. Clinical Safety Laboratory Assessments
See Appendix 2 for the list of clinical safety laboratory tests to be performed and the SoA for 
the timing and frequency. All protocol-required laboratory assessments, as defined in 
Appendix 2, must be conducted in accordance with the laboratory manual and the SoA. 
Unscheduled clinical laboratory measurements may be obtained at any time during the study 
to assess any perceived safety issues.
The investigator must review the laboratory report, document this review, and record any 
clinically significant changes occurring during the study in the AE section of the CRF. 
Clinically significant abnormal laboratory test findings are those that are not associated with 
the underlying disease, unless judged by the investigator to be more severe than expected for 
the participant’s condition.
All laboratory tests with values considered clinically significant and abnormal during 
participation in the study or within 28 days after the last dose of study intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically 
significant by the investigator or study medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by 
the investigator, the etiology should be identified and the sponsor notified.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 54
See Appendix 5 for suggested actions and follow-up assessments in the event of potential 
DILI.
See Appendix 6 for instructions for laboratory testing to monitor kidney function and 
reporting laboratory test abnormalities.
Participants may undergo random urine drug testing at the discretion of the investigator. 
Drug testing conducted prior to dosing must be negative for participants to receive study 
intervention. 
8.3.5. COVID-19 Specific Assessments
Participants will be tested for COVID-19 infection by PCR according to local procedure.
8.3.6. Pregnancy Testing
A urine or serum pregnancy test is required at screening. Following screening, pregnancy 
tests may be urine or serum tests, and must have a sensitivity of at least 25 mIU/mL. 
Pregnancy tests will be performed in WOCBP at the times listed in the SoA. Following a 
negative pregnancy test result at screening, appropriate contraception must be commenced 
and a second negative pregnancy test result will be required at the baseline visit prior to 
starting the study intervention. Pregnancy tests will also be done whenever 1 menstrual cycle 
is missed during the active treatment period (or when potential pregnancy is otherwise 
suspected) and at the end of the study. Pregnancy tests may also be repeated if requested by 
IRBs/ECs or if required by local regulations. If a urine test cannot be confirmed as negative 
(eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant 
must be excluded if the serum pregnancy result is positive.
8.4. Adverse Events, Serious Adverse Events, and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3.
AEs may arise from symptoms or other complaints reported to the investigator by the 
participant (or, when appropriate, by a caregiver, surrogate, or the participant’s legally 
authorized representative), or they may arise from clinical findings of the investigator or 
other healthcare providers (clinical signs, test results, etc).
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study intervention (see Section 7.1). 
During the active collection period as described in Section 8.4.1, each participant will be 
questioned about the occurrence of AEs in a nonleading manner on the days they are at the 
CRU and they will record the AEs on the CRF during remote participation in the study.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 55
In addition, the investigator may be requested by Pfizer Safety to obtain specific follow-up 
information in an expedited fashion.
8.4.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before undergoing any study-related procedure and/or receiving study 
intervention), through and including a minimum of 28 calendar days after the last 
administration of the study intervention.
Follow-up by the investigator continues throughout the active collection period and until the 
AE or SAE or its sequelae resolve or stabilize at a level acceptable to the investigator.
When a clinically important AE remains ongoing at the end of the active collection period, 
follow-up by the investigator continues until the AE or SAE or its sequelae resolve or 
stabilize at a level acceptable to the investigator and Pfizer concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently discontinues or temporarily discontinues study intervention
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to actively seek information on AEs or SAEs after the 
participant has concluded study participation. However, if the investigator learns of any SAE, 
including a death, at any time after a participant has completed the study, and they consider
the event to be reasonably related to the study intervention, the investigator must promptly 
report the SAE to Pfizer using the CT SAE Report Form.
8.4.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.4.1 are reported to Pfizer Safety on the CT SAE Report Form immediately upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any updated SAE data to the sponsor within 
24 hours of its being available.
8.4.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.4.1, will be recorded 
on the AE section of the CRF.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 56
The investigator is to record on the CRF all directly observed and all spontaneously reported 
AEs and SAEs reported by the participant.
As part of ongoing safety reviews conducted by the sponsor, any nonserious AE that is 
determined by the sponsor to be serious will be reported by the sponsor as an SAE. To assist 
in the determination of case seriousness, further information may be requested from the 
investigator to provide clarity and understanding of the event in the context of the clinical 
study.
Reporting of AEs and SAEs for participants who fail screening are subject to the CRF 
requirements as described in Section 5.4.
8.4.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.
8.4.3. Follow-Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow-up (as defined in Section 7.3).
In general, follow-up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality. Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary of available 
autopsy findings must be submitted as soon as possible to Pfizer Safety. 
Further information on follow-up procedures is provided in Appendix 3.
8.4.4. Regulatory Reporting Requirements for SAEs
Prompt notification by the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities toward the safety of participants and the safety of a 
study intervention under clinical investigation are met.
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
sponsor will comply with country-specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRBs/ECs, and investigators.
Investigator safety reports must be prepared for SUSARs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 57
An investigator who receives SUSARs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify the IRB/EC, if appropriate according to local requirements.
8.4.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact with or exposure to the study intervention. Such exposure 
may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, family members, and others who may be exposed. An 
environmental exposure may include EDP, EDB, and occupational exposure.
Any such exposures to the study intervention under study are reportable to Pfizer Safety 
within 24 hours of investigator awareness.
8.4.5.1. Exposure During Pregnancy
An EDP occurs if:

A female participant is found to be pregnant while receiving or after discontinuing 
study intervention.

A male participant who is receiving or has discontinued study intervention
inseminates a female partner.

A female nonparticipant is found to be pregnant while being exposed or having been 
exposed to study intervention because of environmental exposure. Below are 
examples of environmental EDP:  

A female family member or healthcare provider reports that she is pregnant after 
having been exposed to the study intervention by ingestion or skin contact.

A male family member or healthcare provider who has been exposed to the study 
intervention by ingestion or skin contact then inseminates his female partner prior 
to or around the time of conception.
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy). 

If EDP occurs in a participant/participant’s partner, the investigator must report this 
information to Pfizer Safety using the CT SAE Report Form and EDP Supplemental 
Form, regardless of whether an SAE has occurred. Details of the pregnancy will be 
collected after the start of study intervention and until 28 days after the last dose.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 58

If EDP occurs in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study, the information is not recorded on a CRF; however, a copy of the 
completed report is maintained in the investigator site file.
Follow-up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy until 
completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a 
follow-up to the initial report. In the case of a live birth, the structural integrity of the neonate 
can be assessed at the time of birth. In the event of a termination, the reason(s) for 
termination should be specified and, if clinically possible, the structural integrity of the 
terminated fetus should be assessed by gross visual inspection (unless preprocedure test 
findings are conclusive for a congenital anomaly and the findings are reported).
Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomaly in a live-born baby, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy outcomes that are reported to 
Pfizer Safety as SAEs follows: 

Spontaneous abortion including miscarriage and missed abortion should be reported 
as an SAE;

Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality, as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly related to 
exposure to the study intervention. 
Additional information regarding the EDP may be requested by the sponsor. Further 
follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on 
preterm infants to identify developmental delays). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.4.5.2. Exposure During Breastfeeding
An EDB occurs if: 

A female participant is found to be breastfeeding while receiving or after 
discontinuing study intervention.

A female nonparticipant is found to be breastfeeding while being exposed or having 
been exposed to study intervention (ie, environmental exposure). An example of 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 59
environmental EDB is a female family member or healthcare provider who reports 
that she is breastfeeding after having been exposed to the study intervention by 
ingestion or skin contact. 
The investigator must report EDB to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported 
using the CT SAE Report Form. When EDB occurs in the setting of environmental exposure, 
the exposure information does not pertain to the participant enrolled in the study, so the 
information is not recorded on a CRF. However, a copy of the completed report is 
maintained in the investigator site file.
An EDB report is not created when a Pfizer drug specifically approved for use in 
breastfeeding women (eg, vitamins) is administered in accordance with authorized use. 
However, if the infant experiences an SAE associated with such a drug, the SAE is reported 
together with the EDB.
8.4.5.3. Occupational Exposure
The investigator must report any instance of occupational exposure to Pfizer Safety within 
24 hours of the investigator’s awareness using the CT SAE Report Form regardless of 
whether there is an associated SAE. Since the information about the occupational exposure 
does not pertain to a participant enrolled in the study, the information is not recorded on a 
CRF; however, a copy of the completed report is maintained in the investigator site file.
8.4.6. Cardiovascular and Death Events
Not applicable.
8.4.7. Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.4.8. Adverse Events of Special Interest
Not applicable.
8.4.8.1. Lack of Efficacy
This section is not applicable because efficacy is not expected in the study population.
8.4.9. Medical Device Deficiencies
Medical devices being provided for use in this study are those listed in Section 6.1.2. In order 
to fulfill regulatory reporting obligations worldwide, the investigator is responsible for the 
detection and documentation of events meeting the definitions of device deficiency that occur 
during the study with such devices.
The definition of a medical device deficiency can be found in Appendix 9.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 60
Note: AEs and/or SAEs that are associated with a medical device deficiency will follow the 
same processes as other AEs or SAEs, as outlined in Sections 8.4.1 through 8.4.4 and 
Appendix 3 of the protocol.
8.4.9.1. Time Period for Detecting Medical Device Deficiencies
Medical device deficiencies that result in an incident will be detected, documented, and 
reported during all periods of the study in which the medical device is used.
Importantly, reportable device deficiencies are not limited to problems with the device itself 
but also include incorrect or improper use of the device and even intentional misuse, etc.
If the investigator learns of any device deficiency at any time after a participant has been 
discharged from the study, and such deficiency is considered reasonably related to a medical 
device provided for the study, the investigator will promptly notify the sponsor.
Refer to Section 10.9.4 for instructions for documenting and reporting medical device 
deficiencies.
8.4.9.2. Regulatory Reporting Requirements for Device Deficiencies
The investigator will promptly report all device deficiencies occurring with any medical 
device provided for use in the study in order for the sponsor to fulfill the legal responsibility 
to notify appropriate regulatory authorities and other entities about certain safety information 
relating to medical devices being used in clinical studies.
The investigator, or responsible person according to local requirements (eg, the head of the 
medical institution), will comply with the applicable local regulatory requirements relating to 
the reporting of device deficiencies to the IRB/EC.
Note: There are additional reporting obligations for medical device deficiencies that are 
potentially related to SAEs (ie, an SADE) that must fulfill the legal responsibility to notify 
appropriate regulatory authorities and other entities about certain safety information relating 
to medical devices being used in clinical studies.

Any device deficiency that is associated with an SAE must be reported to the sponsor 
within 24 hours after the investigator determines that the event meets the definition of 
a device deficiency.

The sponsor shall review all device deficiencies and determine and document in 
writing whether they could have led to an SAE. These shall be reported to the 
regulatory authorities and IRBs/ECs as required by national regulations.
8.4.10. Medication Errors
Medication errors may result from the administration or consumption of the study 
intervention by the wrong participant, or at the wrong time, or at the wrong dosage strength.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 61
Medication errors are recorded and reported as follows:
Recorded on the 
Medication Error Page 
of the CRF
Recorded on the 
Adverse Event Page 
of the CRF
Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
All (regardless of whether 
associated with an AE)
Any AE or SAE associated 
with the medication error
Only if associated with an 
SAE
Medication errors include:

Medication errors involving participant exposure to the study intervention;

Potential medication errors or uses outside of what is foreseen in the protocol that 
do or do not involve the study participant.

The administration of expired study intervention;

The administration of an incorrect study intervention;

The administration of an incorrect dosage;

The administration of study intervention that has undergone temperature excursion 
from the specified storage range, unless it is determined by the sponsor that the 
study intervention under question is acceptable for use.
Whether or not the medication error is accompanied by an AE, as determined by the 
investigator, such medication errors occurring to a study participant are recorded on the 
medication error page of the CRF, which is a specific version of the AE page and, if 
applicable, any associated serious and nonserious AE(s) are recorded on the AE page of the 
CRF.
In the event of a medication dosing error, the sponsor should be notified within 24 hours.
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
8.5. Pharmacokinetics 
Blood samples of approximately 4 mL, to provide approximately 1.5 mL of plasma, will be 
collected for measurement of plasma concentrations of etrasimod as specified in the SoA.
Instructions for the collection and handling of biological samples will be provided in the 
laboratory manual or by the sponsor. The actual date and time (24-hour clock time) of each 
sample will be recorded.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 62
The actual times may change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of 
samples up to and including 10 hours after dose administration that are obtained within 
10% of the nominal time relative to dosing (eg, within 6 minutes of a 60-minute sample) will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and the CRF. Collection of samples more than 10 hours after dose
administration that are obtained ≤1 hour away from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and the CRF. This protocol deviation window does not apply to samples 
to be collected more than 10 hours after dose administration at outpatient/follow-up visits 
with visit windows.
Samples will be used to evaluate the PK of etrasimod. Samples collected for analyses of 
etrasimod plasma concentration may also be used to evaluate safety or efficacy aspects 
related to concerns arising during or after the study, for protein binding, metabolite 
identification and/or evaluation of the bioanalytical method, or for other internal exploratory 
purposes. The exploratory results may not be reported in the CSR.
Genetic analyses will not be performed on these PK samples.
Samples collected for measurement of plasma concentrations of etrasimod will be analyzed 
using a validated analytical method in compliance with applicable SOPs.
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity. Any deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shipping 
conditions), including any actions taken, must be documented and reported to the sponsor. 
On a case-by-case basis, the sponsor may make a determination as to whether sample 
integrity has been compromised.
Any changes in the timing or addition of time points for any planned study assessments must 
be documented and approved by the relevant study team member and then archived in the 
sponsor and site study files, but will not constitute a protocol deviation. The IRB/EC will be 
informed of any safety issues that require alteration of the safety monitoring scheme or 
amendment of the ICD.
Additional blood samples of approximately 0.5 mL using a micro sampling device (Tasso)
will be collected, to provide approximately 0.25 mL serum into appropriately labeled tubes 
for measurement of etrasimod at selected timepoints as specified in the SoA.
The “Tasso device” is an integrated capillary blood collection device. Blood samples from 
capillary blood vessels, collected using the Tasso device, should be timed as close as possible 
to the collection of etrasimod blood samples. The Tasso device should be attached to the 
upper arm. Details for collection and handling of the samples will be provided in the 
laboratory manual.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 63
The blood samples collected using venous sampling will be used for internal exploratory
purposes for comparing the etrasimod concentrations between venous and capillary blood.
8.6. Genetics
8.6.1. Specified Genetics
Specified genetic analyses are not evaluated in this study.
8.6.2. Retained Research Samples for Genetics
Retained Research Samples for Genetics are not collected in this study.
8.7. Biomarkers
Biomarker assessments are not included in this study.
8.8. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.9. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in the SAP, which will be maintained by the sponsor. 
The SAP may modify what is outlined in the protocol where appropriate; however, any major 
modifications of the primary endpoint definitions or their analyses will also be reflected in a 
protocol amendment.
9.1. Statistical Hypotheses
No statistical hypothesis will be tested in this study.
9.2. Analysis Sets
For purposes of analysis, the following analysis sets are defined:
Participant Analysis Set
Description
Safety Analysis Set
All participants who take at least 1 dose of study 
intervention. Participants will be analyzed according to the 
product they actually received.
PK Concentration Set
All participants who take at least 1 dose of study 
intervention and in whom at least 1 concentration value is 
reported.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 64
Participant Analysis Set
Description
PK Parameter Set
All participants who take at least 1 dose of study 
intervention and in whom at least 1 of the PK parameters of 
interest are reported.
9.3. Statistical Analyses
The SAP will be developed and finalized before database lock and will describe the 
participant populations to be included in the analyses, and procedures for accounting for 
missing, unused, and spurious data. This section is a summary of the planned statistical 
analyses of the primary and secondary endpoints.
9.3.1. Efficacy Analyses
An efficacy analysis is not applicable to this study. 
9.3.2. Safety Analyses
All safety analyses will be performed on the safety population.
AEs, ECGs, BP, pulse rate, and safety laboratory data will be reviewed and summarized on 
an ongoing basis during the study to evaluate the safety of participants. Any clinical 
laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be 
described. Safety data will be presented in tabular and/or graphical format and summarized 
descriptively, where appropriate.
Medical history and physical examination information, as applicable, collected during the 
course of the study, will be considered source data and will not be required to be reported, 
unless otherwise noted. However, any untoward findings identified on physical and/or 
neurological examinations conducted during the active collection period will be captured as 
AEs, if those findings meet the definition of an AE (Appendix 3). Data collected at screening 
that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, 
will be considered source data, and will not be required to be reported, unless otherwise 
noted. Demographic data collected at screening will be reported.
9.3.3. Pharmacokinetic Analyses
Plasma PK parameters of etrasimod will be derived (as data permit) from the 
concentration-time data using standard noncompartmental methods as outlined in the Table 2
below. Actual PK sampling times will be used in the derivation of PK parameters. In the case 
that actual PK sampling times are not available, nominal PK sampling time will be used in 
the derivation of PK parameters. 
Table 2.
Plasma Etrasimod PK Parameters Definitions
Parameter
Definition
Method of Determination
AUCinf
Area under the concentration-time curve from 
time zero extrapolated to infinity
AUClast + (Clast*/kel),


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 65
Table 2.
Plasma Etrasimod PK Parameters Definitions
Parameter
Definition
Method of Determination
where Clast* is the predicted plasma 
concentration at the last quantifiable 
time point from the log-linear 
regression analysis
AUClast
Area under the plasma concentration-time 
profile from time zero to the time of the last 
quantifiable concentration (Clast)
Linear/Log trapezoidal method.
AUC24 hr
Area under the plasma concentration-time 
profile from time zero to 24 hr
Linear/Log trapezoidal method.
AUC24hr-last
Area under the plasma concentration-time 
profile from time 24 hr to the time of the last 
quantifiable concentration (Clast)
Linear/Log trapezoidal method.
Cmax
Maximum observed concentration
Observed directly from data
PK parameters will be summarized descriptively by treatment, in accordance with Pfizer data 
standards. Plasma concentrations will be listed and summarized descriptively by nominal PK 
sampling time and treatment. Individual participant and median profiles of the plasma 
concentration-time data will be plotted by treatment using actual and nominal times, 
respectively. Median profiles will be presented on both linear-linear and log-linear scales.
Natural log transformed AUC24hr, AUC24hr-last, AUCinf, AUClast, and Cmax will be analyzed using 
a mixed effect model with treatment as fixed effect and participant within the sequence as a 
random effect. Treatment F (etrasimod 2 mg, DCT Tasso PK micro samples taken by CRU 
staff and participants) will be the Reference treatment while Treatment G (etrasimod 2 mg, 
DCT Tasso PK micro samples taken by participants only) will be the Test treatment.
Additionally, natural log transformed AUC24hr, AUC24hr-last, AUCinf, AUClast, and Cmax will be 
analyzed using a mixed effect model with treatment as a fixed effect. Treatment A (etrasimod 
2 mg, Main study, venous PK samples) will be the Reference treatment while Treatment F 
(etrasimod 2 mg, DCT Tasso PK micro samples taken by CRU staff and participants) and 
Treatment G (etrasimod 2 mg, DCT Tasso PK micro samples taken by participants only) will 
be the Test treatments.
9.3.4. Micro Sampling and Venous Sampling
Etrasimod concentrations at the predose and 2- and 4-hour postdose sampling time points 
from paired samples obtained via micro sampling and venous sampling will be compared. 
Individual participant differences and % differences of concentrations by PK sampling time, 
will be listed and summarized descriptively. 
9.4. Interim Analyses
No formal interim analysis will be conducted for this study.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 66
9.5. Sample Size Determination
A sample size of 8 participants will provide adequate precision to estimate the rBA of 
etrasimod across studies. These estimates are based on the assumption that standard 
deviations are 0.281 and 0.305 for lnAUCinf and lnCmax, respectively, as obtained from 
studies APD334-007 and APD334-114.
The width of 90% confidence interval for different estimated effects, with 80% coverage 
probability, is presented in the Table 3.
Table 3.
Expected Width of 90% Confidence Interval for Different Possible 
Estimated Effects and Parameters of Interest
Parameter
Estimated Effect
(100*Test/Reference)
90% CI
CI Width
AUC
85%
64.13%
112.67%
48.54%
90%
67.90%
119.29%
51.39%
95%
71.67%
125.92%
54.25%
100%
75.44%
132.55%
57.10%
105%
79.22%
139.17%
59.96%
110%
82.99%
145.80%
62.81%
115%
86.76%
152.43%
65.67%
Cmax
85%
62.60%
115.41%
52.81%
90%
66.29%
122.2%
55.91%
95%
69.97%
128.99%
59.02%
100%
73.65%
135.78%
62.13%
105%
77.33%
142.56%
65.23%
110%
81.02%
149.35%
68.34%
115%
84.70%
156.14%
71.44%
Participants who withdraw from the study or whose study data are determined to be 
non-analyzable may be replaced at the discretion of the investigator upon consultation with 
the sponsor.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 67
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study will be conducted in accordance with the protocol and with the following:

Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;

Applicable ICH GCP guidelines;

Applicable laws and regulations, including applicable privacy laws.
The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents 
(eg, advertisements) must be reviewed and approved by the sponsor, submitted to an IRB/EC 
by the investigator, and reviewed and approved by the IRB/EC before the study is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.
Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study participants.
The investigator will be responsible for the following:

Providing written summaries of the status of the study to the IRB/EC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/EC;

Notifying the IRB/EC of SAEs or other significant safety findings as required by 
IRB/EC procedures;

Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the IRB/EC, European regulation 
536/2014 for clinical studies, European Medical Device Regulation 2017/745 for 
clinical device research, and all other applicable local regulations.
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable 
regulatory authority in any area of the world, or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, Pfizer should be informed immediately.  


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 68
In addition, the investigator will inform Pfizer immediately of any urgent safety measures 
taken by the investigator to protect the study participants against any immediate hazard, and 
of any serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators 
are responsible for providing information on financial interests during the course of the study 
and for 1 year after completion of the study.
10.1.3. Informed Consent Process
The investigator or the investigator’s representative will explain the nature of the study, 
including the risks and benefits, to the participant and answer all questions regarding the 
study. The participant should be given sufficient time and opportunity to ask questions and to 
decide whether or not to participate in the trial.
Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy and data protection requirements, where 
applicable, and the IRB/EC or study center.
The investigator must ensure that each participant is fully informed about the nature and 
objectives of the study, the sharing of data related to the study, and possible risks associated 
with participation, including the risks associated with the processing of the participant’s 
personal data. 
The participant must be informed that their personal study-related data will be used by the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant.
The participant must be informed that their medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/EC members, and by inspectors from regulatory authorities.
The investigator further must ensure that each study participant is fully informed about their
right to access and correct their personal data and to withdraw consent for the processing of 
their personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date on which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the IRB/EC-approved ICD(s) 
during their participation in the study as required per local regulations.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 69
A copy of the ICD(s) must be provided to the participant.
Participants who are rescreened are required to sign a new ICD.
10.1.3.1. Electronic Consent
Participants may be able to experience the informed consent process by electronic means 
(eConsent). The eConsent process includes an electronic presentation of the informed 
consent document (eICD), clinical trial educational components (as applicable), and 
electronic signatures (if allowed by local regulations). The use of eConsent does not replace 
or alter the ICD content or informed consent process as described above. The eConsent 
process complies with applicable regulations and sponsor policies to ensure reliability and 
data privacy.
10.1.4. Data Protection
All parties will comply with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study site in encrypted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only 
authorized study staff have access. The study site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by law.
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant-specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by this single, participant-specific code. The study site will 
maintain a confidential list of participants who participated in the study, linking each 
participant’s numerical code to their actual identity and medical record ID. In case of data 
transfer, the sponsor will protect the confidentiality of participants’ personal data consistent 
with the clinical study agreement and applicable privacy laws.
Information technology systems used to collect, process, and store study-related data are 
secured by technical and organizational security measures designed to protect such data 
against accidental or unlawful loss, alteration, or unauthorized disclosure or access.
The sponsor maintains SOPs on how to respond in the event of unauthorized access, use, or 
disclosure of sponsor information or systems.
10.1.5. Committees Structure
10.1.5.1. Data Monitoring Committee 
This study will not use an E-DMC.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 70
10.1.6. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT/CTIS, and/or 
www.pfizer.com, and other public registries and websites in accordance with applicable local 
laws/regulations. In addition, Pfizer reports study results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study or the country in 
which the study was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer-sponsored interventional 
studies (conducted in patients) that evaluate the safety and/or efficacy of a product, 
regardless of the geographical location in which the study is conducted. These results are 
submitted for posting in accordance with the format and timelines set forth by US law.
EudraCT/CTIS
Pfizer posts clinical trial results on EudraCT/CTIS for Pfizer-sponsored interventional studies 
in accordance with the format and timelines set forth by EU requirements.
www.pfizer.com
Pfizer posts CSR synopses and plain-language study results summaries on www.pfizer.com 
for Pfizer-sponsored interventional studies at the same time the corresponding study results 
are posted to www.clinicaltrials.gov. CSR synopses will have personally identifiable 
information anonymized.
Documents within marketing applications
Pfizer complies with applicable local laws/regulations to publish clinical documents included 
in marketing applications. Clinical documents include summary documents and CSRs 
including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical 
documents will have personally identifiable information anonymized.
Data sharing
Pfizer provides researchers secure access to participant-level data or full CSRs for the 
purposes of “bona-fide scientific research” that contributes to the scientific understanding of 
the disease, target, or compound class. Pfizer will make data from these trials available 
18 months after study completion. Participant-level data will be anonymized in accordance 
with applicable privacy laws and regulations. CSRs will have personally identifiable 
information anonymized.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 71
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is 
responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the CRF.
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securely stored at the study site in encrypted 
electronic and/or paper form and are password-protected or secured in a locked room to 
prevent access by unauthorized third parties.
The investigator must permit study-related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source records and documents.
This verification may also occur after study completion. It is important that the 
investigator(s) and their relevant personnel are available during the monitoring visits and 
possible audits or inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy, including definition of study-critical data items and 
processes (eg, risk-based initiatives in operations and quality, such as risk management and 
mitigation strategies and analytical risk-based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on-site monitoring), are provided in the data management plan and 
monitoring plan maintained and utilized by the sponsor or designee.
The sponsor or designee is responsible for the data management of this study, including 
quality checking of the data.
Records and documents, including signed ICDs, pertaining to the conduct of this study must
be retained by the investigator for 15 years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the sponsor. No records may be 
transferred to another location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securely for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly and irrevocably deleted from all systems.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 72
The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the study. Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly resolve any discrepancies that are identified 
between the study data and the participant’s medical records. The investigator will promptly 
provide copies of the inspection findings to the sponsor or its agent. Before response 
submission to the regulatory authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to any such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or transfer records, depending on 
the study. Also, current medical records must be available.
In this study, the CRF will serve as the source document. A document must be available at 
the investigative site that identifies those data that will be recorded on the CRF and for which 
the CRF will be the source document.
Definition of what constitutes a source document and its origin can be found in the Source 
Document Locator, which is maintained by the Pfizer CRU.
Description of the use of the computerized system is documented in the Data Management 
Plan, which is maintained by the Pfizer CRU.
The investigator must maintain accurate documentation (source record) that supports the 
information entered in the CRF.
The sponsor or designee will perform monitoring to confirm that data entered into the CRF
by authorized site personnel are accurate, complete, and verifiable from source documents; 
that the safety and rights of participants are being protected; and that the study is being 
conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP guidelines, and all applicable regulatory requirements.
10.1.9. Use of Medical Records
There may be instances when copies of medical records for certain cases are requested by 
Pfizer Safety, where ethically and scientifically justified and permitted by local regulations, 
to ensure participant safety.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 73
Due to the potential for a participant to be re-identified from their medical records, the 
following actions must be taken when medical records are sent to the sponsor or sponsor 
designee:

The investigator or site staff must redact personal information from the medical 
record. The personal information includes, but is not limited to, the following:  
participant names or initials, participant dates (eg, birth date, date of hospital 
admission/discharge, date of death), participant identification numbers (eg, Social 
Security number, health insurance number, medical record number, 
hospital/institution identifier), participant location information (eg, street address, 
city, country, postal code, IP address), participant contact information (eg, 
telephone/fax number, email address).

Each medical record must be transmitted to the sponsor or sponsor designee using 
systems with technical and organizational security measures to ensure the protection 
of personal data (eg, Florence is the preferred system if available). 
There may be unplanned situations where the sponsor may request medical records (eg, 
sharing medical records so that the sponsor can provide study-related advice to the 
investigator). The medical records should be submitted according to the procedure described 
above.
10.1.10. Study and Site Start and Closure
The study start date is the date of the first participant’s first visit.
The sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor, including (but not limited to) 
regulatory authority decision, change in opinion of the IRB/EC, or change in benefit-risk 
assessment. Study sites will be closed upon study completion. A study site is considered 
closed when all required documents and study supplies have been collected and a study-site 
closure visit has been performed.
The investigator may initiate study-site closure at any time upon notification to the sponsor if 
requested to do so by the responsible IRB/EC or if such termination is required to protect the 
health of study participants.
Reasons for the early closure of a study site by the sponsor may include but are not limited 
to:

Failure of the investigator to comply with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor’s procedures, or the ICH GCP 
guidelines;

Inadequate recruitment of participants by the investigator;

Discontinuation of further study intervention development.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 74
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory authorities, and any CRO(s) used in the study of 
the reason for termination or suspension, as specified by the applicable regulatory 
requirements. The investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow-up.
Study termination is also provided for in the clinical study agreement. If there is any conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.11. Publication Policy
For multicenter trials, the primary publication will be a joint publication developed by the 
investigator and Pfizer reporting the primary endpoint(s) of the study covering all study sites. 
The investigator agrees to refer to the primary publication in any subsequent publications. 
Pfizer will not provide any financial compensation for the investigator’s participation in the 
preparation of the primary congress abstract, poster, presentation, or primary manuscript for 
the study.
Investigators are free to publish individual center results that they deem to be clinically 
meaningful after publication of the overall results of the study or 12 months after primary 
completion date or study completion at all sites, whichever occurs first, subject to the other 
requirements described in this section.
The investigator will provide Pfizer an opportunity to review any proposed publication or 
any other type of disclosure of the study results (collectively, “publication”) before it is 
submitted or otherwise disclosed and will submit all publications to Pfizer 30 days before 
submission. If any patent action is required to protect intellectual property rights, the 
investigator agrees to delay the disclosure for a period not to exceed an additional 60 days 
upon request from Pfizer. This allows Pfizer to protect proprietary information and to provide 
comments, and the investigator will, on request, remove any previously undisclosed 
confidential information before disclosure, except for any study-intervention or Pfizer-related 
information necessary for the appropriate scientific presentation or understanding of the 
study results. For joint publications, should there be disagreement regarding interpretation 
and/or presentation of specific analysis results, resolution of, and responsibility for, such 
disagreements will be the collective responsibility of all authors of the publication.
For all publications relating to the study, the investigator and Pfizer will comply with 
recognized ethical standards concerning publications and authorship, including those 
established by the International Committee of Medical Journal Editors. The investigator will 
disclose any relationship with Pfizer and any relevant potential conflicts of interest, including 
any financial or personal relationship with Pfizer, in any publications. All authors will have 
access to the relevant statistical tables, figures, and reports (in their original format) required 
to develop the publication.
10.1.12. Sponsor’s Medically Qualified Individual
The contact information for the sponsor’s MQI for the study is documented in the study 
contact list located in the CTMS.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 75
To facilitate access to their investigator and the sponsor’s MQI for study-related medical 
questions or problems from nonstudy healthcare professionals, participants are provided with 
an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol and 
study intervention identifiers, (b) participant’s study identification number, and (c) site 
emergency phone number active 24 hours/day, 7 days per week.
The ECC is intended to augment, not replace, the established communication pathways 
between the participant and their investigator and site staff, and between the investigator and 
sponsor study team. The ECC is only to be used by healthcare professionals not involved in 
the research study, as a means of reaching the investigator or site staff related to the care of a 
participant. 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 76
10.2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests (Table 4) will be performed at times defined in the SoA
section of this protocol. Additional laboratory results may be reported on these samples as a 
result of the method of analysis or the type of analyzer used by the clinical laboratory, or as 
derived from calculated values. These additional tests would not require additional collection 
of blood. Unscheduled clinical laboratory measurements may be obtained at any time during 
the study to assess any perceived safety issues.
Table 4.
Protocol Required Laboratory Assessments
Hematology
Chemistry
Urinalysis
Other
Hemoglobin
Hematocrit
RBC count
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)
Urea/BUN and creatinine
Cystatin Ca
eGFR, eCrClb
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO2 (bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphatase
Uric acid
Albumin
Total protein
Local dipstick:
pH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Laboratory:
Microscopy and 
culturec

Pregnancy test (β-Hcg)f

Urine drug screeninge
At screening:

FSHd

HbsAgg

HbcAbg

HCVAbg

HIV

QuantiFERON- TB Gold 
Testh
a.
Cystatin C (Scys):  Screening or Baseline Scys is recommended to help differentiate post-baseline DIKI 
from DICI. Post-baseline, Scys is measured if and only if serum creatinine increase post-baseline is 
observed (see Section 7.1.1).
b.
Screening and Baseline eGFR or eCrCl is measured with Screat-based formula. Age-specific kidney 
function calculation (see Section 10.6.2) is recommended to assess presence or absence of post-baseline 
change in kidney function.
c.
Only if UTI is suspected and urine dipstick is positive for nitrites or leukocyte esterase or both.
d.
For confirmation of postmenopausal status only in females <60 years old and not using hormonal or 
HRT only.
e.
The minimum requirement for drug screening includes cocaine, THC, opiates/opioids, benzodiazepines, 
and amphetamines (others are site and study-specific).
f.
Local urine testing will be standard for the protocol unless serum testing is required by local regulation 
or IRB/EC. See SoA for collection times.
g.
If HbsAg is negative and HbcAb is positive, HbsAb should be evaluated.
h.
Complete at screening.  Previous testing for QuantiFERON TB Gold Test will be accepted if completed 
within 12 weeks prior to screening. Otherwise, the testing should be completed at screening and results 
available prior to Day 1.
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF.
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may be retained and 
stored for the duration of the study. Upon completion of the study, these retained safety 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 77
samples may be used for the assessment of exploratory safety biomarkers or unexpected 
safety findings. These data will not be included in the CSR. Samples to be used for this 
purpose will be shipped to either a Pfizer-approved BBS facility or other designated 
laboratory and retained for up to 1 year following the completion of the study.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 78
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting
10.3.1. Definition of AE
AE Definition

An AE is any untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether 
or not considered related to the study intervention.

Note: An AE can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of study intervention.
Events Meeting the AE Definition

Any abnormal laboratory test results (hematology, clinical chemistry, or 
urinalysis) or other safety assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator. Any 
abnormal test results that meet any of the conditions below must be recorded as 
an AE:

Is associated with accompanying symptoms;

Requires additional diagnostic testing or medical/surgical intervention;

Leads to a change in study dosing (outside of any protocol-specified dose 
adjustments) or discontinuation from the study, significant additional 
concomitant drug treatment, or other therapy.

Exacerbation of a chronic or intermittent preexisting condition, including an 
increase in either frequency and/or intensity of the condition.

New condition detected or diagnosed after study intervention administration,
even though it may have been present before the start of the study.

Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.

Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 79
Events NOT Meeting the AE Definition

Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.

The disease/disorder being studied or expected progression, signs, or symptoms 
of the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.

Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.

Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).

Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.
10.3.2. Definition of an SAE
An SAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a. Results in death
b. Is life-threatening
The term “life-threatening” in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event that hypothetically might have caused death if it were more severe.
c.
Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been admitted (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the physician’s 
office or outpatient setting. Complications that occur during hospitalization are AEs. 
If a complication prolongs hospitalization or fulfills any other serious criteria, the 
event is serious. When in doubt as to whether “hospitalization” occurred or was 
necessary, the AE should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 80
d. Results in persistent or significant disability/incapacity

The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.

This definition is not intended to include experiences of relatively minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), that may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.
e.
Is a congenital anomaly/birth defect
f.
Is a suspected transmission via a Pfizer product of an infectious agent, 
pathogenic or non-pathogenic 
The event may be suspected from clinical symptoms or laboratory findings 
indicating an infection in a participant exposed to a Pfizer product. The terms 
“suspected transmission” and “transmission” are considered synonymous. These 
cases are considered unexpected and handled as serious expedited cases by 
pharmacovigilance personnel. Such cases are also considered for reporting as 
product defects, if appropriate.
g. Other situations:

Medical or scientific judgment should be exercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations, such as significant 
medical events that may jeopardize the participant or may require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually be considered serious.

Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency or drug abuse.
10.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During the Active 
Collection Period
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs using the CT SAE Report Form to Pfizer Safety throughout the active 
collection period. These requirements are delineated for 3 types of events: (1) SAEs; (2) 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 81
nonserious AEs; and (3) exposure to the study intervention under study during 
pregnancy or breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must 
be completed in a consistent manner. AEs should be recorded using concise medical 
terminology and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event
Recorded on the CRF
Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours 
of Awareness
SAE
All
All
Nonserious AE
All
None
Exposure to the study 
intervention under study 
during pregnancy or 
breastfeeding
All AEs/SAEs associated 
with EDP or EDB
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF
All instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE)**
Environmental or 
occupational exposure 
to the product under 
study to a 
nonparticipant (not 
involving EDP or EDB)
None. Exposure to a study 
nonparticipant is not 
collected on the CRF
The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported***
*
EDP (with or without an associated SAE) is reported to Pfizer Safety using the CT SAE Report 
Form and EDP Supplemental Form. 
** EDB is reported to Pfizer Safety using the CT SAE Report Form, which would also include 
details of any SAE that might be associated with the EDB. 
*** Environmental or occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to Pfizer Safety using the CT SAE Report Form. 

When an AE or SAE occurs, it is the responsibility of the investigator to 
review all documentation (eg, hospital progress notes, laboratory reports, and 
diagnostic reports) related to the event.

The investigator will then record all relevant AE or SAE information in the 
CRF.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 82

It is not acceptable for the investigator to send photocopies of the participant’s 
medical records to Pfizer Safety in lieu of completion of the CT SAE Report 
Form/AE or SAE CRF page.

There may be instances when copies of medical records for certain cases are 
requested by Pfizer Safety. In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the 
medical records before submission to Pfizer Safety. Refer to Section 10.1.9 for 
actions that must be taken when medical records are sent to the sponsor or 
sponsor designee.

The investigator will attempt to establish a diagnosis of the event based on 
signs, symptoms, and/or other clinical information. Whenever possible, the 
diagnosis (not the individual signs/symptoms) will be documented as the AE
or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to 1 of the following categories: 

Mild: A type of AE that is usually transient and may require only minimal 
treatment or therapeutic intervention.  The event does not generally interfere 
with usual ADL.

Moderate: A type of AE that is usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual ADL, causing 
discomfort, but poses no significant or permanent risk of harm to the research 
participant.

Severe: A type of AE that interrupts usual ADL, or significantly affects 
clinical status, or may require intensive therapeutic intervention.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality

The investigator is obligated to assess the relationship between study 
intervention and each occurrence of each AE or SAE. The investigator will use 
clinical judgment to determine the relationship.

A “reasonable possibility” of a relationship conveys that there are facts, 
evidence, and/or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled out.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 83

Alternative causes, such as underlying disease(s), concomitant therapy, and 
other risk factors, as well as the temporal relationship of the event to study 
intervention administration, will be considered and investigated.

The investigator will also consult the IB and/or product information, for 
marketed products, in their assessment.

For each AE or SAE, the investigator must document in the medical notes that 
they have reviewed the AE or SAE and have provided an assessment of 
causality.

There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it 
is very important that the investigator always make an assessment of 
causality for every event before the initial transmission of the SAE data to 
the sponsor.

The investigator may change their opinion of causality in light of follow-up 
information and send an SAE follow-up report with the updated causality 
assessment.

The causality assessment is one of the criteria used when determining 
regulatory reporting requirements.

If the investigator does not know whether or not the study intervention caused 
the event, then the event will be handled as “related to study intervention” for 
reporting purposes, as defined by the sponsor. In addition, if the investigator 
determines that an SAE is associated with study procedures, the investigator 
must record this causal relationship in the source documents and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form 
and in accordance with the SAE reporting requirements.
Follow-Up of AEs and SAEs

The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations, as medically indicated or as 
requested by the sponsor, to elucidate the nature and/or causality of the AE or 
SAE as fully as possible. This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other 
healthcare providers.

If a participant dies during participation in the study or during a recognized 
follow-up period, the investigator will provide Pfizer Safety with a copy of any 
postmortem findings, including histopathology.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 84

New or updated information will be recorded in the originally submitted 
documents.

The investigator will submit any updated SAE data to the sponsor within 24 
hours of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic DCT

The primary mechanism for reporting an SAE to Pfizer Safety will be the 
electronic DCT (eg, eSAE or PSSA).

If the electronic system is unavailable, then the site will use the paper SAE 
report form (see next section) to report the event within 24 hours.

The site will enter the SAE data into the electronic DCT (eg, eSAE or PSSA) 
or paper form (as applicable) as soon as the data become available.

After the study is completed at a given site, the electronic DCT will be taken 
off-line to prevent the entry of new data or changes to existing data.

If a site receives a report of a new SAE from a study participant or receives 
updated data on a previously reported SAE after the electronic DCT has been 
taken off-line, then the site can report this information on a paper SAE form 
(see next section) or to Pfizer Safety by telephone.
SAE Reporting to Pfizer Safety via the CT SAE Report Form

Facsimile transmission of the CT SAE Report Form is one of the methods to 
transmit this information to Pfizer Safety.

In circumstances when the facsimile is not working, an alternative method 
should be used, eg, secured (Transport Layer Security) or password-protected 
email. If none of these methods can be used, notification by telephone is 
acceptable with a copy of the CT SAE Report Form sent by overnight mail or 
courier service.

Initial notification via telephone does not replace the need for the investigator 
to complete and sign the CT SAE Report Form pages within the designated 
reporting time frames.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 85
10.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they agree to the following requirements during 
the intervention period and for at least 28 days after the last dose of study intervention, which 
corresponds to the time needed to eliminate reproductive safety risk of the study 
intervention(s): 

Refrain from donating sperm.
PLUS either:

Be abstinent from heterosexual intercourse as their preferred and usual lifestyle 
(abstinent on a long-term and persistent basis) and agree to remain abstinent.
OR

Must agree to use contraception/barrier as detailed below:

Agree to use a male condom when having sexual intercourse with a pregnant 
or non-pregnant WOCBP.
10.4.2. Female Participant Reproductive Inclusion Criteria
The criteria below are part of Inclusion Criterion 1 (Age and Sex; Section 5.1) and specify 
the reproductive requirements for including female participants. Refer to Section 10.4.4 for a 
complete list of contraceptive methods permitted in the study. 
A female participant is eligible to participate if she (a) is not pregnant or breastfeeding; (b) 
agrees to not donate eggs (ova, oocytes) for the purpose of reproduction for at least 28 days 
after the last dose of study intervention; and (c) at least 1 of the following conditions applies:

Is not a WOCBP (see definition in Section 10.4.3).
OR

Is a WOCBP who agrees to use a highly effective contraceptive method (failure rate 
of <1% per year) with low user dependency during the intervention period and for at 
least 28 days after the last dose of study intervention, which corresponds to the time 
needed to eliminate any reproductive safety risk of the study intervention(s). The 
investigator should evaluate the effectiveness of the contraceptive method in 
relationship to the first dose of study intervention.
OR

Is a WOCBP and agrees to use a highly effective (failure rate of <1% per year) user-
dependent method of contraception during the intervention period and for at least 
28 days after the last dose of study intervention, which corresponds to the time 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 86
needed to eliminate any reproductive safety risk of the study intervention(s). In 
addition to her use of the highly effective method above, she agrees to concurrently
use an effective barrier method. The investigator should evaluate the effectiveness of 
the contraceptive method in relationship to the first dose of study intervention.
The investigator is responsible for reviewing the woman’s medical history, menstrual history,
and recent sexual activity in order to decrease the risk of enrolling a woman with an early,
undetected pregnancy.
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below).
If fertility is unclear (eg, amenorrhea or oligomenorrhea) and a menstrual cycle cannot be 
confirmed before the first dose of study intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
1.
Premenopausal female with 1 of the following:

Documented hysterectomy;

Documented bilateral salpingectomy;

Documented bilateral oophorectomy.
For individuals with permanent infertility due to a medical cause other than the above
(eg, mullerian agenesis, androgen insensitivity), investigator discretion should be applied 
to determining study entry.
Note: Documentation for any of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history 
interview. The method of documentation should be recorded in the participant’s medical 
record for the study.
2.
Postmenopausal female.

A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition:

A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 

A female on HRT and whose menopausal status is in doubt will be required to 
use one of the highly effective nonestrogen hormonal contraception methods 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 87
if she wishes to continue her HRT during the study. Otherwise, she must 
discontinue HRT to allow confirmation of postmenopausal status before study 
enrollment.
10.4.4. Contraception Methods
Contraceptive use by men or women should be consistent with local availability/regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
The following contraceptive methods are appropriate for this study:
Highly Effective Methods That Have Low User Dependency 
1. Implantable progestogen-only hormone contraception associated with inhibition of 
ovulation.
2. Intrauterine device.
3. Intrauterine hormone-releasing system.
4. Bilateral tubal occlusion.
5. Vasectomized partner.

Vasectomized partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed.  If not, an additional highly effective method of contraception 
should be used.  The spermatogenesis cycle is approximately 90 days.
Highly Effective Methods That Are User Dependent 
6. Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation:

Oral + barrier*

Intravaginal + barrier*

Transdermal + barrier*


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 88
7. Progestogen-only hormone contraception associated with inhibition of ovulation:

Oral + barrier*

Injectable + barrier*
* Acceptable barrier methods to be used concomitantly with options 6 or 7 for the 
study include any of the following:
o
Male or female condom with or without spermicide;
o
Cervical cap, diaphragm, or sponge with spermicide;
o
A combination of male condom with either cervical cap, diaphragm, or 
sponge with spermicide (double-barrier methods).
8. Sexual Abstinence
9. Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study intervention.  The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual 
lifestyle of the participant.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 89
10.5. Appendix 5: Liver Safety: Suggested Actions and Follow-Up Assessments 
Potential Cases of Drug-Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury (as determined by elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury but adapt 
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are 
“susceptible” to progressive and serious liver injury, commonly referred to as DILI. 
Participants who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently to determine if they are “adaptors” or are “susceptible.”
In the majority of DILI cases, elevations in AST and/or ALT precede T bili elevations 
(>2 × ULN) by several days or weeks. The increase in T bili typically occurs while 
AST/ALT is/are still elevated above 3 × ULN (ie, AST/ALT and T bili values will be 
elevated within the same laboratory sample). In rare instances, by the time T bili elevations 
are detected, AST/ALT values might have decreased. This occurrence is still regarded as a 
potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to T bili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law 
criteria) cases and should always be considered important medical events, even before all 
other possible causes of liver injury have been excluded.
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions. Participants who present 
with the following laboratory abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:

Participants with AST/ALT and T bili baseline values within the normal range who 
subsequently present with AST OR ALT values ≥3 × ULN AND a T bili value ≥2 × ULN 
with no evidence of hemolysis and an alkaline phosphatase value <2 × ULN or not 
available.

For participants with baseline AST OR ALT OR T bili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:

Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values ≥2 times the baseline values AND ≥3 × ULN; or ≥8 × ULN (whichever is 
smaller).

Preexisting values of T bili above the normal range: T bili level increased from 
baseline value by an amount of ≥1 × ULN or if the value reaches ≥3 × ULN 
(whichever is smaller).
Rises in AST/ALT and T bili separated by more than a few weeks should be assessed 
individually based on clinical judgment; any case where uncertainty remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 90
The participant should return to the investigator site and be evaluated as soon as possible, 
preferably within 48 hours from awareness of the abnormal results. This evaluation should 
include laboratory tests, detailed history, and physical assessment. 
In addition to repeating measurements of AST, ALT, and T bili for suspected Hy’s law cases, 
additional laboratory tests should include albumin, CK, direct and indirect bilirubin, GGT, 
PT/INR, eosinophils (%), and alkaline phosphatase. Consideration should also be given to 
drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analyses at the time of the recognized initial 
abnormalities to determine etiology. A detailed history, including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by itself or as a coformulated 
product in prescription or over-the-counter medications), recreational drug, or supplement 
(herbal) use and consumption, family history, sexual history, travel history, history of contact 
with a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection, total bile acids, liver imaging (eg, biliary tract), and 
collection of serum samples for acetaminophen/paracetamol drug and/or protein adduct 
levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and 
T bili elevation defined above should be considered potential DILI (Hy’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable investigations have been received and have excluded an alternative etiology.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 91
10.6. Appendix 6: Kidney Safety: Monitoring Guidelines
10.6.1. Laboratory Assessment of Change in Kidney Function and Detection of Kidney 
Injury
Standard kidney safety monitoring requires assessment of baseline and postbaseline Screat 
measurement to estimate kidney function [Screat-based eGFR] or creatinine clearance 
[eCrCl]). Obtaining Screening or Baseline Scys and postbaseline reflex Scys (if confirmed 
Screat increase ≥0.3 mg/dL) makes it feasible to distinguish AKI from DICI. If Screat 
increase is confirmed after baseline, then reflex measurement of Scys is indicated:
ADULTS: Currently, 2021 CKD-EPI eGFR equations (Screat only-based and combined 
Screat plus Scys-based) are valid for use in adults only. At baseline Screat and Scys values 
are needed to calculate 2021 CKD-EPI eGFR by Screat only-based equation (see 
Table 10.6.2.1.) and by combined Screat plus Scys-based equation. When post-baseline 
Screat increase ≥0.3 mg/dL is confirmed, then reflex Scys measurement is needed to enable 
post-baseline comparison of eGFR changes (Screat only-based eGFR and combined Screat 
plus Scys eGFR). 
Regardless of whether kidney function monitoring tests are required as a routine safety 
monitoring procedure in the study, if the investigator or sponsor deems it necessary to further 
assess kidney safety and quantify kidney function, then these test results should be managed 
and followed per standard of care.
10.6.2. Age-Specific Kidney Function Calculation Recommendations
10.6.2.1. Adults (18 Years and Above)—2021 CKD-EPI Equations
eGFR (mL/min/1.73m²)13
2021 
CKD-EPI
Screat Only
Screat
(mg/dL)
Scys
(mg/L)
Recommended eGFR Equation
Female
if ≤ 0.7
N/A
eGFR = 143 × (Screat/0.7)-0.241  ×  (0.9938)Age
Female
if > 0.7
N/A
eGFR = 143 × (Screat/0.7)-1.200  ×  (0.9938)Age
Male
if ≤ 0.9
N/A
eGFR = 142 × (Screat/0.9)-0.302  ×  (0.9938)Age
Male
if > 0.9
N/A
eGFR = 142 × (Screat/0.9)-1.200  ×  (0.9938)Age
2021 
CKD-EPI 
Screat-Scys 
Combined
Screat
(mg/dL)
Scys
(mg/L)
Recommended eGFR Equation
Female
if ≤ 0.7
if ≤ 0.8
eGFR = 130 × (Screat/0.7)-0.219  × (Scys/0.8)-0.323  × (0.9961)Age
Female
if ≤ 0.7
if > 0.8
eGFR = 130 × (Screat/0.7)-0.219  × (Scys/0.8)-0.778  × (0.9961)Age
Female
if > 0.7
if ≤ 0.8
eGFR = 130 × (Screat/0.7)-0.544  × (Scys/0.8)-0.323  × (0.9961)Age
Female
if > 0.7
if > 0.8
eGFR = 130 × (Screat/0.7)-0.544  × (Scys/0.8)-0.778  × (0.9961)Age
Male
if ≤ 0.9
if ≤ 0.8
eGFR = 135 × (Screat/0.9)-0.144  × (Scys/0.8)-0.323  × (0.9961)Age
Male
if ≤ 0.9
if > 0.8
eGFR = 135 × (Screat/0.9)-0.144  × (Scys/0.8)-0.778  × (0.9961)Age
Male
if > 0.9
if ≤ 0.8
eGFR = 135 × (Screat/0.9)-0.544  ×  (Scys/0.8)-0.323  × (0.9961)Age
Male
if > 0.9
if > 0.8
eGFR = 135 × (Screat/0.9)-0.544  ×  (Scys/0.8)-0.778  × (0.9961)Age


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 92
10.6.3. Kidney Function Calculation Tool
The sponsor has provided the following resources to investigational sites when required to 
calculate age-specific kidney function at Screening, Baseline, and post-Baseline visits.  Site 
calculations of kidney function can be performed manually, using the age-appropriate
formulae (see Section 10.6.2) and can use recommended online kidney function calculators 
to reduce the likelihood of a calculation error. 
The United States National Kidney Foundation Online Calculators. 

Adults (18 years and above) – 2021 CKD-EPI Creatinine Online Calculator (eGFR): 
https://www.kidney.org/professionals/KDOQI/gfr_calculator
Investigational sites are responsible to ensure that the accurate age-specific equation is 
selected and that the correct units for serum creatinine (mg/dL only), serum cystatin C (mg/L 
only), total body weight (kg only), and age (years). Investigators are expected to (i) review 
and confirm correctness of the kidney function calculation results and (ii) evaluate the 
calculated value within the context of historical information available to them in the 
participant’s medical record. Investigators are responsible for the clinical oversight of the 
participant eligibility process, kidney function calculation, and dose selection and 
adjustments per study protocol. Investigators are encouraged to direct questions or 
uncertainties regarding kidney function and dosing to the Pfizer Clinical Team and Medical 
Monitor, if needed.
10.6.4. Adverse Event Grading for Kidney Safety Laboratory Abnormalities
AE grading for decline in kidney function (ie, eGFR or eCrCl) will be according to Kidney
Disease: Improving Global Outcomes (KDIGO) criteria for adult participants.
KDIGO criteria 
grade (G)
Study 
Population
G1
G2
G3
G4
G5
Decreased 
Kidney Function 
due to either 
Acute or Chronic 
Kidney Injury 
Adult 
participants
eGFR 
(mL/min/1.73m²)
≥90 
≥60 to 89
30 to 59 
15 to 29
<15


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 93
KDIGO albuminuria 
(A) criteria
A1
A2
A3
Albumin-to-creatinine 
ratio (ACR)
<30 mg/g
OR
<3 mg/mmol 
30 to 300 mg/g
OR
3 to 30 mg/mmol
>300 mg/g 
OR
>30 mg/mmol


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 94
10.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as AEs

Marked sinus bradycardia (rate <40 bpm) lasting minutes.

New PR interval prolongation >280 ms.

New prolongation of QTcF to >480 ms (absolute).

New prolongation of QTcF by >60 ms from baseline.

New-onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate <120 bpm.

New-onset type I second-degree (Wenckebach) AV block of >30-second duration.

Frequent PVCs, triplets, or short intervals (<30 seconds) of consecutive 
ventricular complexes.
ECG Findings That May Qualify as SAEs

QTcF prolongation >500 ms.

Absolute value of QTcF > 450 ms AND QTcF change from baseline >60 ms.

New ST-T changes suggestive of myocardial ischemia.

New-onset LBBB (QRS complex>120 ms).

New-onset right bundle branch block (QRS complex>120 ms).

Symptomatic bradycardia.

Asystole:

In awake, symptom-free participants in sinus rhythm, with documented 
asystolic pauses ≥3 seconds or any escape rate <40 bpm, or with an escape 
rhythm that is below the AV node;

In awake, symptom-free participants with atrial fibrillation and bradycardia 
with 1 or more asystolic pauses of at least 5 seconds or longer. 

Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 95

Sustained supraventricular tachycardia (rate >120 bpm) (“sustained” = short 
duration with relevant symptoms or lasting >1 minute).

Ventricular rhythms >30 seconds’ duration, including idioventricular rhythm (HR
<40 bpm), accelerated idioventricular rhythm (HR >40 bpm to <100 bpm), and 
monomorphic/polymorphic ventricular tachycardia (HR >100 bpm [such as
torsades de pointes]).

Type II second-degree (Mobitz II) AV block.

Complete (third-degree) heart block.
ECG Findings That Qualify as SAEs

Change in pattern suggestive of new myocardial infarction.

Sustained ventricular tachyarrhythmias (>30-second duration).

Second- or third-degree AV block requiring pacemaker placement.

Asystolic pauses requiring pacemaker placement.

Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.

Ventricular fibrillation/flutter.

At the discretion of the investigator, any arrhythmia classified as an adverse 
experience.
The major events of potential clinical concern listed above are recommended as “alerts” or notifications 
from the core ECG laboratory to the investigator and Pfizer study team, and not to be considered as all-
inclusive of what is to be reported as AEs/SAEs.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 96
10.8. Appendix 8: Prohibited Concomitant Medications That May Result in DDI
The prohibited concomitant medications listed below should not be taken with etrasimod for 
the period of time at least equal to the required washout period listed in the table, and 
throughout the conduct of the study.  
The Pfizer study team is to be notified of any prohibited medications taken during the study. 
After consulting with the sponsor, the investigator will make a judgment on the ongoing 
participation of any participant with prohibited medication use during the study.
This list of drugs prohibited for potential DDI concerns with the IMP may be revised during 
the course of the study with written notification from sponsor, to include or exclude specific 
drugs or drug categories for various reasons (eg, emerging DDI results for the IMP, 
availability of new information in literature on the DDI potential of other drugs), if the 
overall benefit:risk assessment is not impacted or if the changes do not significantly impact 
the safety of participants or the scientific value of the trial.
This is not an all-inclusive list. Site staff should consult with the sponsor or designee with 
any questions regarding potential DDI.
Drug Category 
Drugs
Required Washout Period Requirement
Dual Moderate 
CYP2C9 and 
Moderate to 
Strong 
CYP3A4
Inhibitors
fluconazole
2 weeks 
or
5 half-lives
whichever is longer
Moderate to 
Strong 
Inducers of 
CYP2C8 
CYP2C9 
CYP3A4
enzalutamide 
rifampicin
5 half-lives plus 14 days
For example, carbamazepine:
The average half-life of carbamazepine after 
repeat dosing is on average 15 hours, so the 
washout period is calculated as the sum of 5 half-
lives (approximately 3 days) and an additional 14 
days for a total of 17 days.
Investigators should consult the SRSD for active comparator for information regarding 
medication that is prohibited for concomitant use. 
Investigators should consult the product label for any other medication used during the study 
for information regarding medication that is prohibited for concomitant use. 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 97
10.9. Appendix 9: AEs, ADEs, SAEs, SADEs, USADEs, and Device Deficiencies: 
Definitions and Procedures for Recording, Evaluating, Follow-Up, and Reporting in 
Medical Device Studies
Definitions of a Medical Device Deficiency
The definitions and procedures detailed in this appendix are in accordance with ISO 14155 
and the European MDR 2017/745 for clinical device research (if applicable). 
Both the investigator and the sponsor will comply with all local reporting requirements for 
medical devices.
The detection and documentation procedures described in this protocol apply to all sponsor 
medical devices provided for use in the study (see Section 6 for the list of sponsor medical 
devices).
10.9.1. Definition of AE and ADE
AE and ADE Definition 

An AE is defined in Appendix 3 (Section 10.3.1).

An ADE is defined as an AE related to the use of an investigational medical 
device. This definition includes any AEs resulting from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or 
operation, or any malfunction of the investigational medical device as well as 
any event resulting from use error or from intentional misuse of the 
investigational medical device.
10.9.2. Definition of SAE, SADE, and USADE
SAE Definition:

An SAE is defined in Appendix 3 (Section 10.3.2). 
SADE Definition

An SADE is defined as an ADE that has resulted in any of the consequences 
characteristic of an SAE.

Any device deficiency that might have led to an SAE if appropriate action had 
not been taken, intervention had not occurred, or circumstances had been less 
fortunate.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 98
USADE Definition

A USADE (also identified as UADE in US Regulations 21 CFR 813.3) is an
SADE that by its nature, incidence, severity, or outcome has not been identified 
in the current version of the risk analysis management file.
10.9.3. Definition of Device Deficiency
Device Deficiency Definition

A device deficiency is an inadequacy of a medical device with respect to its 
identity, quality, durability, reliability, safety, or performance. Device 
deficiencies include malfunctions, use errors, and inadequate information 
supplied by the manufacturer.
10.9.4. Recording/Reporting and Follow-Up of Medical Device Deficiencies
Device Deficiency Recording

When a device deficiency occurs, it is the responsibility of the investigator to 
review all documentation (eg, hospital progress notes, laboratory reports, and 
diagnostic reports) related to the event.

The investigator will then record all relevant device deficiency information in the 
participant’s medical records, in accordance with the investigator’s normal 
clinical practice, and will also capture the required information on the Medical 
Device Complaint Form.

It is not acceptable for the investigator to send photocopies of the participant’s 
medical records to Pfizer Safety in lieu of following the reporting process 
described in the Medical Device Complaint Form.

There may be instances when copies of medical records for certain cases are 
requested by Pfizer Safety. In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the medical 
records before submission to Pfizer Safety. Refer to Section 10.1.9 for actions 
that must be taken when medical records are sent to the sponsor or sponsor 
designee.

If the investigator determines that the medical device deficiency may have 
injured the participant (ie, the medical device deficiency is associated with an AE 
or SAE), then the investigator will attempt to establish a diagnosis of the event 
based on signs, symptoms, and/or other clinical information. Whenever possible, 
the diagnosis will be documented in the participant’s medical record and 
recorded as the AE or SAE rather than the individual signs/symptoms. 


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 99
Requirements for recording and reporting an AE or SAE are provided in 
Appendix 3 (Section 10.3.3).

For device deficiencies, it is very important that the investigator describes any 
corrective or remedial actions taken to prevent recurrence of the incident.

A remedial action is any action other than routine maintenance or servicing 
of a medical device where such action is necessary to prevent recurrence of a 
device deficiency. This includes any amendment to the device design to 
prevent recurrence.
Assessment of Causality Occurring in Conjunction With a Medical Device 
Deficiency

If an AE or SAE has occurred in conjunction with a medical device deficiency, 
the investigator must assess the relationship between each occurrence of the AE 
or SAE and the medical device deficiency. The investigator will use clinical 
judgment to determine the relationship.

A “reasonable possibility” of a relationship conveys that there are facts, 
evidence, and/or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled out.

Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.

The investigator will also consult the IB in their assessment.

For each device deficiency, the investigator must document in the medical notes 
that they have reviewed the device deficiency and have provided an assessment 
of causality.

There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to the sponsor.

The investigator may change their opinion of causality in light of follow-up 
information and send an SAE follow-up report with the updated causality 
assessment.

The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 100
Follow-Up of Medical Device Deficiency

The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations, as medically indicated or as 
requested by the sponsor, to elucidate the nature and/or causality of the device 
deficiency as fully as possible. This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other 
healthcare providers.

New or updated information regarding the nature of the device deficiency will be 
recorded in the originally completed Medical Device Complaint Form.

New or updated information regarding any SAE that was potentially associated 
with the medical device deficiency will be submitted to Pfizer Safety on the CT 
SAE Report Form within 24 hours of receipt of the information, according to the 
requirements provided in Appendix 3.
10.9.5. Reporting of SAEs
Reporting of an SAE to Pfizer Safety must be performed according to the processes 
described in Appendix 3 (Section 10.3.4).
10.9.6. Reporting of SADEs
SADE Reporting to Pfizer Safety 
Note: There are additional reporting obligations for medical device deficiencies that are 
potentially related to SAEs (ie, an SADE) that must fulfill the legal responsibility to 
notify appropriate regulatory authorities and other entities about certain safety 
information relating to medical devices being used in clinical studies.

Any device deficiency that is associated with an SAE must be reported to the 
sponsor within 24 hours after the investigator determines that the event meets the 
definition of a device deficiency.

The sponsor shall review all device deficiencies and determine and document in 
writing whether they could have led to an SAE. These shall be reported to the 
regulatory authorities and IRBs/ECs as required by national regulations.


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 101
10.10. Appendix 10: Abbreviations
The following is a list of abbreviations that may be used in the protocol. 
Abbreviation
Term
A1 to A3
albuminuria (KDIGO albuminuria severity standardization)
AA
alopecia areata
Abs
absolute
ACR
albumin-to-creatinine ratio
AD
atopic dermatitis
ADE
adverse device effect
ADL
activity/activities of daily living
AE
adverse event
AKI
acute kidney injury
ALC
absolute lymphocyte count
ALT
alanine aminotransferase
ANC
absolute neutrophil count
AST
aspartate aminotransferase
AUC
area under the curve
AUC0-24
area under the plasma concentration-time curve over the last 24 h 
dosing interval
AUCinf
Area under the concentration-time curve from time zero 
extrapolated to infinity
AUClast
Area under the plasma concentration-time profile from time zero to 
the time of the last quantifiable concentration (Clast)
AV
atrioventricular
AxMP
auxiliary medicinal product
BA
bioavailability
BBS
Biospecimen Banking System
-Hcg
-human chorionic gonadotropin
BMI
body mass index
BP
blood pressure
bpm
beats per minute
BUN
blood urea nitrogen
CFR
Code of Federal Regulations
CI
confidence interval
CIOMS
Council for International Organizations of Medical Sciences
CK
creatine kinase
CKD-EPI
Chronic Kidney Disease Epidemiology Collaboration
Clast
the last quantifiable concentration
CL/F
apparent clearance
Cmax
maximum observed concentration
CNS
cardiopulmonary nervous system
CO2
carbon dioxide (bicarbonate)
COVID-19
coronavirus disease 2019


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 102
Abbreviation
Term
CRF
case report form
CRO
Contract Research Organization
CRU
clinical research unit
CSR
Clinical Study Report
Ctrough
predose trough concentration
CT
clinical trial
CTMS
Clinical Trial Management System
CTIS
Clinical Trial Information System
CYP
cytochrome P450
DCT
data collection tool/decentralized clinical trial
DDI
drug-drug interaction 
DHT
digital health technology
DICI
drug-induced creatinine increase
DIKI
drug-induced kidney injury
DILI
drug-induced liver injury
EBV
Epstein-Barr virus
EC50
half maximal effective concentration
EC
ethics committee
ECC
emergency contact card
ECG
electrocardiogram or electrocardiography
eCrCl
estimated creatinine clearance
eCRF
electronic case report form
EDB
exposure during breastfeeding
E-DMC
External Data Monitoring Committee
EDP
exposure during pregnancy
eGFR
estimated glomerular filtration rate
EoE
eosinophilic esophagitis
eSAE
electronic serious adverse event
ET
early termination
EU
European Union
EudraCT
European Union Drug Regulating Authorities Clinical Trials 
(European Clinical Trials Database)
FPFV
first participant first visit
FSH
follicle-stimulating hormone
F/U
follow-up
G1 to G5
Grade (KDIGO eGFR category standardization)
GCP
Good Clinical Practice
GIRK
G-protein-gated inwardly rectifying potassium
GGT
gamma-glutamyl transferase
HbcAb
hepatitis B core antibody
HBsAb
hepatitis B surface antibody
HbsAg 
hepatitis B surface antigen
HCVAb
hepatitis C antibody


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 103
Abbreviation
Term
HDPE
high-density polyethylene
hERG
human ether-a-go-go gene
HIV
human immunodeficiency virus
HR
heart rate
HRT
hormone replacement therapy
IB
Investigator’s Brochure
IC50
half maximal inhibitory concentration
ICD
informed consent document
ICH
International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use
ID
identification
IMP
investigational medicinal product
IND
Investigational New Drug 
INR
international normalized ratio
IPAL
Investigational Product Accountability Log
IPM
investigational product manual
IR
immediate release
IRB
Institutional Review Board
ISO
International Organization for Standardization
IV
intravenous
KDIGO
Kidney Disease Improving Global Outcomes
LBBB
left bundle branch block
LFT
liver function test
MDR
medical device regulation
MMR
Measles, Mumps, Rubella
MQI
medically qualified individual
MS
multiple sclerosis
NDA
New Drug Application
NIMP
noninvestigational medicinal product
PCR
polymerase chain reaction
PCRU
Pfizer Clinical Research Unit
PD
pharmacodynamic(s)
PE
physical examination
PK
pharmacokinetic(s)
PPD
purified protein derivative
PR
pulse rate
PSSA
Pfizer's Serious Adverse Event Submission Assistant
PT
prothrombin time
PVC
premature ventricular contraction/complex
QFT-G
QuantiFERON-TB Gold
QTc
corrected QT interval
QTcF
QTc corrected using Fridericia’s formula
qual
qualitative


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 104
Abbreviation
Term
Rac
accumulation ratio
rBA
relative bioavailability
RBC
red blood cell
SADE
serious adverse device effect
SAE
serious adverse event
SAP
Statistical Analysis Plan
Screat
serum creatinine
Scys
serum cystatin C
S1P
sphingosine 1-phosphate
S1P1
S1P receptor 1
S1P1,4,5
S1P receptors 1, 4, and 5
SDEI
sponsor-designated event of interest
SoA
schedule of activities
SOP
standard operating procedure
SRSD
Single Reference Safety Document
SUSAR
Suspected Unexpected Serious Adverse Reaction
t½
terminal half-life
TB
tuberculosis 
T bili
total bilirubin
TEAE
treatment emergent adverse event
THC
tetrahydrocannabinol
Tmax
time for Cmax
UC
ulcerative colitis
ULN
upper limit of normal
US
United States
USADE
unanticipated serious adverse device effect
UTI
urinary tract infection
Vz/F
apparent volume of distribution
WBC
white blood cell
WOCBP
woman/women of childbearing potential


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 105
11. REFERENCES
1
FDA. Decentralized clinical trials for drugs, biological products, and devices. May 
2023. Available from: Decentralized Clinical Trials for Drugs, Biological Products, and 
Devices | FDA. Accessed: 09 Aug 2023.
2
EMA. Recommendation paper on decentralised elements in clinical trials. Version 01, 
13 Dec 2022. Available from: mp_decentralised-elements_clinical-trials_rec_en.pdf 
(europa.eu). Accessed: 09 Aug 2023.
3
FDA. Guidance for industry: enhancing the diversity of clinical trial populations -
eligibility criteria, enrollment practices, and trial designs. November 2020. Available 
from: Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, 
Enrollment Practices, and Trial Designs Guidance for Industry | FDA. Accessed: 09 Aug 
2023.
4
Ivanova-Nikolova TT, Nikolov EN, Hansen C, et al. Muscarinic K+ channel in the
heart. Modal regulation by G protein beta gamma subunits. J Gen Physiol. 
1998;112(2):199-210.
5
Camm J, Hla T, Bakshi R, Brinkmann V. Cardiac and vascular effects of fingolimod:
mechanistic basis and clinical implications. Am Heart J. 2014;168(5):632-44.
6
Sykes DA, Riddy DM, Stamp C, et al. Investigating the molecular mechanisms through 
which FTY720-P causes persistent S1P1 receptor internalization. Br J Pharmacol. 
2014;171(21):4797-807.
7
Taylor S, Gray JR, Willis R, et al. The utility of pharmacokinetic-pharmacodynamic 
modeling in the discovery and optimization of selective S1P1 agonists. Xenobiotica. 
2012;42(7):671-86.
8
GILENYA® (fingolimod) United States Prescribing Information. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022527s031lbl.pdf. 
Accessed: 05 Feb 2023.
9
Mayzent® (siponimod) United States Prescribing Information. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209884s015lbl.pdf. 
Accessed: 05 Feb 2023.
10
Zeposia® (ozanimod) United States Prescribing Information. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209899s005lbl.pdf.
Accessed: 05 Feb 2023.
                                                


Etrasimod
Protocol C5041050
Final Protocol Amendment 2, 06 Nov 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 106
11
Ponvory™ (ponesimod) United States Prescribing Information. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s001lbl.pdf. 
Accessed: 05 Feb 2023.
12
Cartier A, Hla T. Sphingosine 1-phosphate: Lipid signaling in pathology and therapy. 
Science. 366(6463):eaar5551.
13
Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based 
Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-49.


Document Approval Record
Document Name:
	 
	       
!
Document Title:
	 
	       
!
Signed By:
Date(GMT)
Signing Capacity
( ( 	)*)	
+,! && !
/( ( 	)/)
+,! && !
PPD
PPD

SAP_001.pdf: 
Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 1 of 16
Protocol C5041050
A Phase 1, Open-Label, Single Dose, Fixed-Sequence Crossover Sub Study to 
Determine the Pharmacokinetics Using Tasso Device and Safety and Tolerability 
Using Wearable Monitoring Devices Following Single Oral Doses of Etrasimod 2 mg 
IR Tablets in Healthy Adult Participants in a Hybrid Decentralized Clinical Trial Design
Statistical Analysis Plan 
(SAP)
Version:
1
Date:
22 Dec 2023


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 2 of 16
TABLE OF CONTENTS
LIST OF TABLES..................................................................................................................3
APPENDICES.......................................................................................................................3
1. VERSION HISTORY .........................................................................................................4
2. INTRODUCTION...............................................................................................................4
2.1. Modifications to the Analysis Plan Described in the Protocol.................................4
2.2. Study Objectives, Endpoints, and Estimands ........................................................4
2.3. Study Design.........................................................................................................5
3. ENDPOINTS AND BASELINE VARIABLES: DEFINITIONS AND CONVENTIONS ..........6
3.1. Primary Endpoints.................................................................................................6
3.2. Secondary Endpoints ............................................................................................6
3.2.1. PK Parameters from Tasso and Venous Blood Sampling .........................6
3.2.2. Safety Endpoints.......................................................................................6
3.2.2.1. First Dose HR reduction...........................................................7
3.2.2.2. Adverse Events........................................................................7
3.2.2.3. Laboratory Data .......................................................................7
3.2.2.4. Vital Signs................................................................................7
3.2.2.5. Electrocardiograms ..................................................................7
3.3. Other Safety Endpoint(s).......................................................................................7
3.4. Exploratory Endpoint.............................................................................................8
3.5. Baseline Variables ................................................................................................8
4. ANALYSIS SETS (POPULATIONS FOR ANALYSIS) .......................................................8
5. GENERAL METHODOLOGY AND CONVENTIONS.........................................................8
5.1. Hypotheses and Decision Rules............................................................................8
5.2. General Methods...................................................................................................8
5.2.1. Analyses for Binary/Categorical Endpoints................................................8
5.2.2. Analyses for Continuous Endpoints...........................................................8
5.3. Methods to Manage Missing Data.........................................................................9
5.3.1. Pharmacokinetic Data...............................................................................9
5.3.2. Safety Data.............................................................................................10
6. ANALYSES AND SUMMARIES ......................................................................................10
6.1. Primary Endpoints...............................................................................................10
6.2. Secondary Endpoints ..........................................................................................10
6.2.1. PK Parameters from Tasso and Venous Blood Sampling .......................10


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 3 of 16
6.2.2. Safety Endpoints.....................................................................................11
6.2.2.1. First Dose HR reduction.........................................................11
6.2.2.2. Adverse Events......................................................................11
6.2.2.3. Laboratory Data .....................................................................11
6.2.2.4. Vital Signs..............................................................................11
6.2.2.5. Electrocardiograms ................................................................11
6.3. Other Safety Summaries and Analyses Endpoint(s)............................................11
6.4. Exploratory Endpoint...........................................................................................11
6.4.1. Plasma Concentrations of Etrasimod ......................................................11
6.5. Subset Analyses .................................................................................................12
6.6. Baseline and Other Summaries and Analyses ....................................................12
6.6.1. Demographic Summaries........................................................................12
6.6.2. Study Conduct and Participant Disposition..............................................12
6.6.3. Study Treatment Exposure .....................................................................12
6.6.4. Concomitant Medications and Nondrug Treatments................................13
7. INTERIM ANALYSES......................................................................................................13
LIST OF TABLES
Table 1.
Summary of Changes..............................................................................4
Table 2.
Definitions of PK Parameters ..................................................................6
Table 3.
PK Parameters to be Summarized Descriptively by Treatment .............10
APPENDICES
Appendix 1. SAS Code for Analyses ...................................................................................14
Appendix 2. List of Abbreviations ........................................................................................15


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 4 of 16
NOTE: Italicized text within this document has been taken verbatim from the Protocol.
1. VERSION HISTORY
Table 1.
Summary of Changes
Version/
Date
Associated 
Protocol 
Amendment
Rationale
Specific Changes
1 /
22 Dec 2023
Amendment 2
06 Nov 2023
N/A
N/A
2. INTRODUCTION
Etrasimod is an orally administered, selective, synthetic S1P1,4,5 modulator that is being 
developed to treat immune-mediated inflammatory disorders, including UC, AA, AD, CD and 
EoE. The S1P1 is a cell surface expressed protein that has been shown to regulate 
lymphocyte migration out of lymphoid tissues. Synthetic small molecule S1P1 agonists have
been observed to act as functional antagonists by inducing sustained receptor 
internalization, thus inhibiting lymphocyte migration out of lymphoid tissues and lowering the 
amount of peripheral blood lymphocytes available to be recruited to sites of inflammation. 
Modulation of the S1P/S1P receptor axis is thought to be a potential therapeutic approach to 
the management of immune-mediated inflammatory disorders.
This sub study is being conducted to assess the feasibility of conducting a Phase 1 
etrasimod study as a hybrid decentralized clinical trial with dosing by study personnel at the 
CRU and remote collection of PK, safety and tolerability data. The specific objectives of the 
sub study are to determine the PK and to assess the safety and tolerability of etrasimod 
clinical IR tablets 2 mg under fasted conditions in healthy adult participants in a hybrid DCT 
design.
This SAP provides the detailed methodology for summary and statistical analyses of the 
data collected in Study C5041050. 
2.1. Modifications to the Analysis Plan Described in the Protocol
PK concentration and parameters pertaining to Tasso OnePlus micro sampling will be 
regarded as results from serum etrasimod in summary tables and listings, while PK 
concentration and parameters derived from venous sampling will be regarded as results 
from plasma etrasimod.
2.2. Study Objectives, Endpoints, and Estimands
The following are the objectives and endpoints in this study. Estimand framework will not be 
applied to this Phase 1 study in healthy participants.


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 5 of 16
Objectives
Endpoints
Primary: 
Primary: 
To compare the PK of etrasimod 2 mg 
clinical IR tablets under fasted conditions in 
healthy participants using Tasso OnePlus 
PK micro samples taken by participants only 
(Treatment G) vs. CRU staff and participants 
(Treatment F) in a hybrid DCT design

Plasma AUC24hr, AUC24hr-last, AUCinf (if data 
permit, otherwise AUClast) and Cmax of 
etrasimod
Secondary: 
Secondary: 
To compare the PK of etrasimod 2 mg 
clinical IR tablets under fasted conditions in 
healthy participants using Tasso OnePlus 
PK micro samples taken by participants only 
(Treatment G) vs. CRU staff and participants 
(Treatment F) in a hybrid DCT design vs. 
venous PK samples taken by CRU staff in 
conventional design of main study 
(Treatment A)
To evaluate the safety and tolerability of 
etrasimod 2 mg clinical IR tablets in healthy 
participants using mobile wearable devices 
in a hybrid DCT design
Plasma AUC24 hr, AUC24hr-last, AUCinf (if data 
permit, otherwise AUClast) and Cmax of 
etrasimod
Assessment of first dose HR reduction, 
TEAEs, clinical laboratory abnormalities, vital 
signs, PEs, and ECGs
Tertiary/Exploratory:
Tertiary/Exploratory:
To compare the concentrations of etrasimod 
in PK samples collected using Tasso 
OnePlus micro sampling device against 
those using venous blood sampling. 
Plasma concentrations of etrasimod obtained 
via micro sampling compared to venous 
sampling at pre-dose and at 2 and 4 hrs post-
dose.
2.3. Study Design
This is a Phase 1, open-label, single-dose, fixed-sequence, crossover study in a single
cohort of approximately 8 healthy male or female participants conducted using a hybrid DCT
design.
The study will consist of 2 treatments. Participants will receive the two Treatments F and G
in a fixed sequence as shown below. There will be an 8-day washout between each dose.
Fixed Treatment 
Sequence (n=8)
Period 1
Period 2
1
F
G
Treatment F: Single oral dose of etrasimod 2 mg, DCT with practice sessions* (Reference)
Treatment G: Single oral dose of etrasimod 2 mg, DCT without practice sessions** (Test)
* Practice of Tasso and Wearable Monitoring Devices on Day 2 at CRU; participant self-assessment remotely for vitals and 
ECG (Days 3-5) and PK samples (Days 3-8)
** Participant self-assessment using Tasso and Wearable Monitoring Devices on Days 1-2 at CRU; and remotely on Days 
3-8


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 6 of 16
3. ENDPOINTS AND BASELINE VARIABLES: DEFINITIONS AND CONVENTIONS
3.1. Primary Endpoints
The primary endpoints are the plasma AUC24hr, AUC24hr-last, AUCinf (if data permit, otherwise 
AUClast) and Cmax of etrasimod. The test/reference ratios for AUC24 hr, AUC24hr-last, AUCinf,
AUClast and Cmax will be derived with Treatment G (etrasimod 2 mg, DCT Tasso PK micro 
samples taken by participants only) as the test treatment and Treatment F (etrasimod 2 mg,
DCT Tasso PK micro samples taken by CRU staff and participants) as the reference 
treatment.
Plasma PK parameters of etrasimod will be derived (as data permit) from the 
concentration-time data using standard noncompartmental methods as outlined in the 
Table 2 below. Actual PK sampling times will be used in the derivation of PK parameters. In 
the case that actual PK sampling times are not available, nominal PK sampling time will be 
used in the derivation of PK parameters.
Table 2.
Definitions of PK Parameters
Parameter
Definition
Method of Determination
AUCinf
Area under the concentration-time curve 
from time zero extrapolated to infinity
AUClast + (Clast*/kel),
where Clast* is the predicted plasma 
concentration at the last quantifiable 
time point from the log-linear 
regression analysis
AUClast
Area under the plasma concentration-time 
profile from time zero to the time of the last 
quantifiable concentration (Clast)
Linear/Log trapezoidal method.
AUC24hr
Area under the plasma concentration-time 
profile from time zero to 24 hr
Linear/Log trapezoidal method.
AUC24hr-last
Area under the plasma concentration-time
profile from time 24 hr to the time of the last
quantifiable concentration (Clast)
Linear/Log trapezoidal method.
Cmax
Maximum observed concentration
Observed directly from data
3.2. Secondary Endpoints
3.2.1. PK Parameters from Tasso and Venous Blood Sampling
The test/reference ratios for AUC24hr, AUC24hr-last, AUCinf, AUClast and Cmax will be derived with 
Treatment A (etrasimod 2 mg, Main study, venous PK samples) as the Reference treatment
while Treatment F (etrasimod 2 mg, DCT Tasso PK micro samples taken by CRU staff and 
participants) and Treatment G (etrasimod 2 mg, DCT Tasso PK micro samples taken by 
participants only) as the Test treatments.
3.2.2. Safety Endpoints
The following data are considered in standard safety summaries (see protocol for collection
days, baseline assessment, and list of parameters):

first dose HR reduction

adverse events (AE)


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 7 of 16

laboratory data

vital signs data

electrocardiogram (ECG) results
3.2.2.1. First Dose HR reduction
For all periods, HR will be measured every hour up to 6 hours, at 8 and 24 hours post-
etrasimod dose at Day 1. The baseline HR value is the average of the HR values from the 
triplicate ECG measurements collected predose on Day 1 of each period. Changes from 
baseline will be defined as the change between the postdose measurements and baseline 
value. In addition, the nadir HR value on Day 1 will be derived.
3.2.2.2. Adverse Events
Any adverse events occurring following start of treatment will be considered as treatment 
emergent adverse event (TEAE). Events that occur during follow-up within the lag time of up 
to 35 days after the last dose of study intervention will be counted as treatment emergent 
and attributed to the last treatment taken. The time period for collecting AEs (“active 
collection period”) for each participant begins from the time the participant provides informed 
consent.
3.2.2.3. Laboratory Data
Safety laboratory tests will be performed as described in the protocol.
For all periods, the baseline measurement is the predose measurement on Day -1 in each 
period. Changes from baseline will be defined as the change between the postdose and 
baseline measurements.
3.2.2.4. Vital Signs
Supine blood pressure (BP), pulse rate (PR) and temperature will be measured at times 
specified in the SoA given in the protocol.
For all periods, the baseline measurement is the predose measurement on Day 1 in each 
period. Changes from baseline will be defined as the change between the postdose and 
baseline measurements.
3.2.2.5. Electrocardiograms
QT interval, QTcF, PR interval, QRS and heart rate (HR) will be recorded at each 12-lead 
ECG assessment time indicated in the SoA given in the protocol. QTcF will be derived using 
Fridericia’s heart rate correction formula:
QTcF = QT / (RR)^(1/3) where RR = 60/HR (if not provided)
For all periods, the baseline value is the average of triplicate ECG measurements collected 
predose on Day 1 of each period. Changes from baseline will be defined as the change 
between the postdose measurements and baseline value.
3.3. Other Safety Endpoint(s)
None.


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 8 of 16
3.4. Exploratory Endpoint
Plasma concentrations of etrasimod obtained via micro sampling (taken by participants only 
and taken by CRU staff and participants) compared to venous sampling at predose and at 2 
and 4 hours postdose.
3.5. Baseline Variables
Baseline characteristics will be collected according to the schedule of activities (SoA) as 
specified in the protocol. 
4. ANALYSIS SETS (POPULATIONS FOR ANALYSIS)
Data for all participants will be assessed to determine if participants meet the criteria for 
inclusion in each analysis population prior to releasing the database and classifications will 
be documented per standard operating procedures.
Participant Analysis Set
Description
Safety Analysis Set
All participants who take at least 1 dose of study intervention. 
Participants will be analyzed according to the product they actually 
received.
PK Concentration Set
All participants who take at least 1 dose of study intervention and in 
whom at least 1 concentration value is reported.
PK Parameter Set
All participants who take at least 1 dose of study intervention and in 
whom at least 1 of the PK parameters of interest are reported.
5. GENERAL METHODOLOGY AND CONVENTIONS
Final analysis will be performed after study participant data set release following last 
participant last visit.
5.1. Hypotheses and Decision Rules
No statistical hypothesis will be tested in this study.
5.2. General Methods
5.2.1. Analyses for Binary/Categorical Endpoints
For binary or categorical variables, number of participants, numbers and percentages of 
participants meeting the categorical criteria will be presented in accordance with the Clinical 
Data Interchange Standards Consortium and Pfizer Standards (CaPS).
5.2.2. Analyses for Continuous Endpoints
For continuous variables, the data will be summarized using the number of participants, 
mean, median, standard deviation (SD), minimum, and maximum in accordance with the 
CaPS. For appropriate PK parameters, geometric mean and geometric coefficient of 
variation (%CV) will also be summarized.


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 9 of 16
5.3. Methods to Manage Missing Data
5.3.1. Pharmacokinetic Data
Methods to handle missing PK data are described below. 
Concentrations Below the Limit of Quantification:
In all data presentations (except listings), concentrations below the limit of quantification 
(BLQ) will be set to zero. In listings, BLQ values will be reported as “<LLQ”, where LLQ will 
be replaced with the value for the lower limit of quantification.
Deviations, Missing Concentrations and Anomalous Values:
In summary tables and plots of median profiles, statistics will be calculated having set
concentrations to missing if one of the following cases is true:
1. A concentration has been collected as ND (ie, not done) or NS (ie, no sample).
2. A deviation in sampling time is of sufficient concern or a concentration has been
flagged anomalous by the pharmacokineticist.
Note that summary statistics will not be presented at a particular time point if more than 50% 
of the data are missing.
An anomalous concentration value is one that, after verification of bioanalytical validity, is 
grossly inconsistent with other concentration data from the same individual or from other 
participants. For example, a BLQ concentration that is between quantifiable values from the 
same dose is considered as anomalous. Anomalous concentration values may be excluded 
from PK analysis at the discretion of the PK analyst.
PK Parameters:
Actual PK sampling times will be used in the derivation of PK parameters. If a PK parameter 
cannot be derived from a participant’s concentration data, the parameter will be coded as 
NC (ie, not calculated). (Note that NC values will not be generated beyond the day that a 
participant discontinues).
In summary tables, statistics will not be presented for a particular treatment group if more 
than 50% of the data are NC. For statistical analyses, PK parameters coded as NC will also 
be set to missing, and statistics will be presented for a particular treatment with >3 evaluable 
measurements.
If an individual participant has a known biased estimate of a PK parameter (due for example 
to a dosing error or an unexpected event such as vomiting before all the compound is 
adequately absorbed from the gastrointestinal tract), this will be footnoted in summary tables 
and will not be included in the calculation of summary statistics or statistical analyses.  For 
instance, if a participant has a vomiting event post dose that is within a duration of time that 
is 2-times the derived median Tmax for the population for the administered treatment, then 
the pharmacokineticist should consider the exclusion of the PK concentration data collected 
following the initial vomiting event in that treatment period and the PK parameter data 
reported for that treatment period from the datasets used to calculate summary statistics or 
statistical analyses.


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 10 of 16
5.3.2. Safety Data
Missing values in standard summaries of safety data will be imputed according to CaPS.
6. ANALYSES AND SUMMARIES
6.1. Primary Endpoints
Plasma AUC24hr, AUC24hr-last, AUClast, AUCinf and Cmax of etrasimod will be summarized by 
treatment group and will include the set of summary statistics as specified in Table 3.
Table 3.
PK Parameters to be Summarized Descriptively by Treatment 
Parameter
Summary Statistics
AUC24hr, AUC24hr-last,
AUCinf, AUClast, Cmax
N, arithmetic mean, median, SD, %CV, minimum, maximum, 
geometric mean and geometric %CV
Natural log transformed AUC24hr, AUC24hr-last, AUCinf, AUClast, and Cmax will be analyzed using 
a mixed effect model with treatment as a fixed effect and participant as random effect. 
Estimates of the adjusted mean differences (Test-Reference) and corresponding 90% CIs 
will be obtained from the model. The adjusted mean differences and 90% CIs for the 
differences will be exponentiated to provide estimates of the ratio of adjusted geometric 
means (Test/Reference) and 90% CI for the ratios. Treatment F (etrasimod 2 mg, DCT 
Tasso PK micro samples taken by CRU staff and participants) will be the Reference 
treatment while Treatment G (etrasimod 2 mg, DCT Tasso PK micro samples taken by 
participants only) will be the Test treatment.
A listing of the individual participant ratios (Test/Reference) will be provided. Box and 
whisker plots for AUC24hr, AUC24hr-last, AUCinf, AUClast and Cmax, will be plotted by treatment 
and overlaid with geometric means.
Residuals from the models will be examined for normality and the presence of outliers via 
visual inspection of plots of residuals vs predicted values and normal probability plots of 
residuals but these will not be included in the CSR. If there are major deviations from 
normality or outliers then the effect of these on the conclusions will be investigated through 
alternative transformations and/or analyses excluding outliers. Justification for any 
alternative to the planned analysis will be given in the report of the study.
6.2. Secondary Endpoints
6.2.1. PK Parameters from Tasso and Venous Blood Sampling
Natural log transformed AUC24hr, AUC24hr-last, AUCinf, AUClast, and Cmax will be analyzed using 
an ANOVA with treatment as a fixed effect. Estimates of the adjusted mean differences 
(Test-Reference) and corresponding 90% CIs will be obtained from the model. The adjusted 
mean differences and 90% CIs for the differences will be exponentiated to provide estimates 
of the ratio of adjusted geometric means (Test/Reference) and 90% CI for the ratios. 
Treatment A (etrasimod 2 mg, Main study, venous PK samples) will be the Reference 
treatment while Treatment F (etrasimod 2 mg, DCT Tasso PK micro samples taken by CRU 
staff and participants) and Treatment G (etrasimod 2 mg, DCT Tasso PK micro samples 
taken by participants only) will be the Test treatments.


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 11 of 16
6.2.2. Safety Endpoints
All safety analyses will be performed on the Safety Analysis Set.
Safety data will be presented in tabular and/or graphical format and summarized 
descriptively, where appropriate.
6.2.2.1. First Dose HR reduction
Changes from predose baseline in HR at every hour up to 6 hours, at 8 and 24 hours on 
Day 1 and on Days 3 to 5, as well as the nadir HR value on Day 1 of each period, will be 
summarized by treatment.
6.2.2.2. Adverse Events
TEAEs will be reported in accordance with the CaPS.
Participant discontinuations due to adverse events will be detailed by treatment. Data will be 
reported in accordance with the CaPS.
6.2.2.3. Laboratory Data
Laboratory data will be listed and summarized by treatment in accordance with the CaPS.
6.2.2.4. Vital Signs
Vital sign data will be listed and summarized by treatment in accordance with the CaPS.
6.2.2.5. Electrocardiograms
ECG data will be listed and summarized by treatment in accordance with the CaPS.
Changes from baseline for the ECG parameters will be summarized by treatment. The 
number (%) of participants with maximum postdose QTcF values and maximum increases 
from baseline in the following categories will be tabulated by treatment.
Degree of 
Prolongation
Mild (ms)
Moderate (ms)
Severe (ms)
Absolute value
>450 – 480
>480 – 500
>500
Increase from baseline
30-60
>60
6.3. Other Safety Summaries and Analyses Endpoint(s)
None.
6.4. Exploratory Endpoint
6.4.1. Plasma Concentrations of Etrasimod
The plasma concentrations will be listed and descriptively summarized by nominal PK 
sampling time and treatment. Individual participant, as well as mean and median profiles of 
the plasma concentration-time data will be plotted by treatment using actual (for individual) 
and nominal (for mean and median) times respectively. Mean and median profiles will be 
presented on both linear and semi-log scales.


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 12 of 16
Presentations of concentrations will include:

A listing of all concentrations sorted by participant ID, treatment and nominal time
postdose. The concentration listing will also include the actual times. Deviations from the 
nominal time will be given in a separate listing.

A summary of concentrations by treatment and nominal time postdose, where the set of 
statistics will include n, mean, median, SD, %CV, minimum, maximum and the number 
of concentrations above the LLQ.

Median concentrations time plots (on both linear and semi-log scales) against nominal 
time postdose by treatment (all treatments on the same plot per scale, based on the 
summary of concentrations by treatment and time postdose).

Mean concentrations time plots (on both linear and semi-log scales) against nominal
time postdose by treatment (all treatments on the same plot per scale, based on the 
summary of concentrations by treatment and time postdose).

Individual concentration-time plots by treatment (on both linear and semi-log scales) 
against actual time postdose (there will be separate spaghetti plots for each treatment 
per scale).

Individual concentration-time plots by participant (on both linear and semi-log scales)
against actual time postdose [there will be separate plots for each participant (containing
all treatments) per scale].
Etrasimod concentrations at the predose and 2- and 4-hour postdose sampling time points 
from paired samples obtained via micro sampling and venous sampling will be compared.
Individual participant differences and % differences of concentrations by PK sampling time,
will be listed and summarized descriptively.
6.5. Subset Analyses
There are no planned subset analyses.
6.6. Baseline and Other Summaries and Analyses
6.6.1. Demographic Summaries
Demographic characteristics will be summarized for Safety Analysis Set in accordance with 
the CaPS.
6.6.2. Study Conduct and Participant Disposition
Participants evaluation groups will show end of study participant disposition. Frequency 
counts will be supplied for participant discontinuation(s) by treatment. Data will be reported 
in accordance with the CaPS.
6.6.3. Study Treatment Exposure
Study treatment exposure will be listed.


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 13 of 16
6.6.4. Concomitant Medications and Nondrug Treatments
All prior and concomitant medication(s) as well as non-drug treatment(s) will be reported in 
the listings.
7. INTERIM ANALYSES
No formal interim analysis will be conducted for this study. As this is an open-label study, the 
sponsor may conduct unblinded reviews of the data during the course of the study for the 
purpose of safety assessment, facilitating PK/PD modeling, and/or supporting clinical 
development.
Final analysis will follow the official database release.  As this will be an open-label study, 
there is no formal unblinding of the randomization code.


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 14 of 16
Appendix 1. SAS Code for Analyses
An example of the PROC MIXED code is provided below:
For the primary objective (G vs F):
proc mixed data=tab.pk;
class trt participant;
model l&var= trt/ ddfm=KR;
random participant/subject=participant;
lsmeans trt;
estimate ‘G vs F’ trt -1 1  /cl alpha=0.1;
ods ‘Estimates’ out=est&var;
ods ‘lsmeans’ out=ls&var;
ods ‘covparms’ out=cov&var;
ods ‘tests3’ out=tst&var;
run;
For the secondary objective (G or F vs A):
proc mixed data=tab.pk;
class trt;
model l&var= trt/ ddfm=KR;
lsmeans trt;
     estimate 'F vs A' trt -1 1 0 /cl alpha=0.1;
estimate ‘G vs A’ trt -1 0 1  /cl alpha=0.1;
ods 'Estimates' out=est&var;
ods 'lsmeans' out=ls&var;
ods 'covparms' out=cov&var;
ods 'tests3' out=tst&var;
run;
/* Letter assignments for treatments (trt) within the estimate statement above are as follows
Treatment A: Single oral dose of etrasimod 2 mg clinical IR tablet under fasted conditions 
(from C5041034, Reference for the secondary endpoint analysis)
Treatment F: Single oral dose of etrasimod 2 mg, DCT with practice sessions [DCT Tasso 
PK micro samples taken by CRU staff and participants] (Reference for the primary endpoint 
analysis, Test for the secondary endpoint analysis)
Treatment G: Single oral dose of etrasimod 2 mg, DCT without practice sessions [DCT 
Tasso PK micro samples taken by participants only] (Test for the primary and secondary
endpoint analyses)
*/


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 15 of 16
Appendix 2. List of Abbreviations
Abbreviation
Term
%CV
coefficient of variation
AA
alopecia areata
AD
atopic dermatitis
AE
adverse event
ANOVA
analysis of variance
AUC24hr
area under the plasma concentration-time profile from time zero to 24 hr
AUC24hr-last
Area under the plasma concentration-time profile from time 24 hr to the time of the 
last quantifiable concentration
AUCinf
area under the plasma concentration-time profile from time zero extrapolated to 
infinite time
AUClast
area under the plasma concentration-time profile from time zero to the time of the 
last quantifiable concentration
BLQ
below the limit of quantification
BP
blood pressure
CaPS
Clinical Data Interchange Standards Consortium and Pfizer Standards
CD
Crohn’s Disease
CI
confidence interval
Clast
last quantifiable concentration
Cmax
maximum plasma concentration
CRU
clinical research unit
CSR
clinical study report
DCT
decentralized clinical trial
ECG
electrocardiogram
EoE
eosinophilic esophagitis
HR
heart rate
IR
immediate-release
kel
terminal phase rate constant
LLQ
lower limit of quantification
mg
milligram
ms
millisecond
N/A
not applicable
NC
not calculated
ND
not done
NS
no sample
PD
pharmacodynamic(s)
PE
physical examination
PK
pharmacokinetic(s)
PR
pulse rate
PR interval
time from the beginning of the P wave to the beginning of the QRS complex
QRS
combination of Q-, R- and S- wave on an electrocardiogram representing ventricular
depolarization
QT
time from the start of the Q- wave to the end of T- wave, which represents time 
taken for ventricular depolarization and repolarization 
QTc
corrected QT
QTcF
corrected QT (Fridericia method)
RR
time between the start of one QRS complex and the start of the next QRS complex
SAP
statistical analysis plan
SD
standard deviation
S1P
sphingosine 1-phosphate
S1P1,4,5
S1P receptors 1, 4, and 5


Protocol C5041050 (PF-07915503) Statistical Analysis Plan
PFIZER CONFIDENTIAL 
DMB02-GSOP-RF02 8.0 Statistical Analysis Plan Template
TMF Doc ID: 98.03
Page 16 of 16
Abbreviation
Term
SoA
schedule of activities
TEAE
treatment emergent adverse event
Tmax
time to Cmax
UC
ulcerative colitis